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9iii. Abstract 
Background. Kidney transplantation (KTX) is considered to be the best 
treatment of terminal uremia. Despite improvements in short-term graft  
survival, a considerable number of kidney allograft s are lost due to the pre-
mature death of patients with a functional kidney and to chronic allograft  
nephropathy (CAN).
Aim. To investigate the risk factors involved in the progression of CAN 
and to analyze diagnostic methods for this entity.
Materials and methods. Altogether, 153 implant and 364 protocol biop-
sies obtained between June 1996 and April 2008 were analyzed. Th e biop-
sies were classifi ed according to Banff  ’97 and chronic allograft  damage 
index (CADI). Immunohistochemistry for TGF-β1 was performed in 49 
biopsies. Kidney function was evaluated by creatinine and/or cystatin C 
measurement and by various estimates of glomerular fi ltration rate (GFR). 
Demographic data of the donors and recipients were recorded aft er 2 years’ 
follow-up.
Results. Most of the 3-month biopsies (73%) were nearly normal. Th e 
mean CADI score in the 6-month biopsies decreased signifi cantly aft er 
2001. Diastolic hypertension correlated with ΔCADI. Serum creatinine 
concentration at hospital discharge and glomerulosclerosis were risk fac-
tors for ΔCADI. High total and LDL cholesterol, low HDL and hyperten-
sion correlated with chronic histological changes. Th e mean age of the do-
nors increased from 41–52 years. Older donors were more oft en women 
who had died from an underlying disease. Th e prevalence of delayed graft  
function increased over the years, while acute rejections (AR) decreased 
signifi cantly over the years. Sub-clinical AR was observed in 4% and it did 
not aff ect long-term allograft  function or CADI. Recipients´ drug treat-
ment was modifi ed along the Studies, being mycophenolate mophetil, tac-
rolimus, statins and blockers of the renine-angiotensin-system more fre-
quently prescribed aft er 2001.
Patients with a higher ΔCADI had lower GFR during follow-up. CADI 
over 2 was best predicted by creatinine, although with modest sensitivity 
and specifi city. Neither cystatin C nor other estimates of GFR were supe-
rior to creatinine for CADI prediction. Cyclosporine A toxicity was seldom 
seen. Low cyclosporin A concentration aft er 2 h correlated with TGF-β1 
expression in interstitial infl ammatory cells, and this predicted worse graft  
function.
Conclusions. Th e progression of CAN has been aff ected by two major 
factors: the donors’ characteristics and the recipients’ hypertension. Th e 
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increased prevalence of DGF might be a consequence of the acceptance of 
older donors who had died from an underlying disease. Implant biopsies 
proved to be of prognostic value, and they are essential for comparison 
with subsequent biopsies. Th e progression of histological damage was as-
sociated with hypertension and dyslipidemia. Th e augmented expression 
of TGF-β1 in infl ammatory cells is unclear, but it may be related to low 
immunosuppression. Serum creatinine is the most suitable tool for moni-
toring kidney allograft  function on every-day basis. However, protocol bi-
opsies at 6 and 12 months predicted late kidney allograft  dysfunction and 
aff ected the clinical management of the patients. Protocol biopsies are thus 
a suitable surrogate to be used in clinical trials and for monitoring kidney 
allograft s.
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1. Introduction
Since the fi rst successful kidney transplantation (KTX ) in 1954 between 
identical twins, a new modality to treat patients with terminal kidney 
insuffi  ciency was born. Although the results in the fi rst decades were mo-
dest, continuous improvement has characterized this fascinating fi eld. A 
major breakthrough was the introduction of the new immunosuppressant 
cyclosporine A (CsA) in the early 1980s. Th e fundament of its success was 
the ability to improve kidney graft  survival considerably over the fi rst year, 
and CsA is the cornerstone of immunosuppression even in the present 
decade. 
KTX is considered the most suitable method for treating terminal ure-
mia, taking into consideration patient’s outcome, quality of life and cost 
of treatment. Th e number of patients receiving a kidney transplant has in-
creased during the past years. We are witnessing a remarkable growth in 
the number of patients entering dialysis, and unfortunately this is not pa-
ralleled by an equal increase in the kidney donor pool. Th e obvious conse-
quence is that patients remain longer on dialysis while waiting for a kidney 
transplant. Several attempts to rectify this imbalance have been made, such 
as augmenting the donor pool by expanding the criteria for donation, e.g. 
by accepting cardiac death donors, and promoting living donation. Th e si-
tuation remains critical despite these eff orts, and the increasing number of 
patients dying while waiting for a transplant is alarming. According to the 
newsletter of the Council of Europe, by December 2007, a total of 50,223 
European dialysis patients were on the waiting list, and in the same year, 
938 patients died while waiting for a kidney transplant.
Th e improvement of graft  survival during the fi rst years aft er transplan-
tation has been largely achieved through a reduction in the rate of acute 
rejection (AR) episodes. In the Finnish population the AR rate fell from 
37% in the mid-1980s to 20% at the beginning of this century (Salmela, 
2004), and even lower rates, around 10%, have been reported in the past 
few years (Kyllönen, personal communication). Th is improvement was re-
fl ected in the longer kidney graft  survival, which increased at fi ve years 
from 73% to 94%. Despite the fact that short-term graft  survival has im-
proved considerably over the past 10 years, a similar success has not yet 
been achieved in the long run. Th e loss of functional kidneys due to the 
premature death of transplanted patients is of great concern. Th is repre-
sents the most common cause of graft  loss, in addition to chronic allo-
graft  nephropathy (CAN). It is thus of vital importance to understand the 
mechanisms involved in the relentless damage of a kidney transplant. Th e 
12
aim is to prolong the survival of kidney allograft s in order to overcome the 
shortage of donors. 
Th e studies described in the following were conducted with the inten-
tion to elucidate some of the complex mechanisms behind the pathogen-
esis and prognosis of CAN, and to search for accurate methods for diag-
nosing it.
13
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2. Pathophysiology of 
chronic allograft nephropathy (CAN): 
Immune-dependent factors
Th e term CAN was proposed in 1991, and it replaced the previously used 
term “chronic rejection”. Th e intention was to unify chronic histological 
changes seen under light microscopy, such us interstitial fi brosis, tubular 
atrophy, transplant glomerulopathy and vasculopathy. Th e pathophysiolo gy 
behind each of these features may nevertheless be diff erent. Th e processes 
involved are approached by dividing them roughly into immunological 
and non-immunological factors, although they may be interrelated.
 
2.1. HLA antigens present in the donor but absent in the recipient are 
counted as HLA-mismatches. HLA-A, -B and -DR mismatches have been 
associated with poor graft  survival. Although organ allocation relies on 
several non-immunological and logistic factors, a close HLA match is de-
sirable. A report on the eff ect of HLA-mismatch on cadaver kidney allo-
graft  survival in 1999 was based on data reported by 301 transplantation 
centers. It was clearly demonstrated that the greater the number of mis-
matches, the poorer the survival at 5 years of follow-up. (Opelz, 1999) In 
2004 data from cadaver kidney transplants performed during 1994 and 
1998 were collected from the United Network of Organ Sharing (UNOS) 
and the United States Renal Data System (URSD). Altogether 33,433 re-
cipients were followed up for 2.2 years and, in addition to HLA-mismatch, 
the eff ect of non-immunological factors such as cold ischemia time, donor 
age, gender and cause of death, donor and recipient body size were also 
analyzed. Th e authors concluded that the signifi cance of HLA-matching 
is diminishing in the era of new immunosuppressive drugs, but that the 
impact of non-immunological factors on survival had remained unaltered.
(Su, 2004) More effi  cacious immunosuppressive regimens (i.e. tacrolimus, 
mycophenolate mophetil (MMF), induction therapies) have gained popu-
larity aft er the year 2000. Th e importance of HLA-mismatch in this era 
of modern immunosuppression was re-evaluated in the largest European 
study, where the results of two eras: 1985–1994 and 1995–2004, were com-
pared. A total of 135,970 cadaver kidney transplants were followed up 
for 5 years. Although the survival rates improved over the years, HLA-
mismatches still had a clear impact. A multiregression analysis of factors 
contributing to graft  survival revealed that the impact of HLA-mismatches 
on graft  survival was equally strong in the two decades compared.(Opelz, 
2007)
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2.2. Sensitization to foreign HLA is observed in patients on the transplant 
waiting list. Th e main routes of sensitization are blood transfusion, preg-
nancy and transplantation. Th e increased use of erythropoietin lessened 
the need for blood transfusions. Although leukodepleted transfusions are 
routinely used, they can still stimulate the production of HLA antibodies.
(van de Watering, 2003) Antibodies can be identifi ed in several ways, but 
the most commonly used is the complement-dependent toxicity test. Th e 
patient’s serum is tested against a panel of lymphocytes from HLA-typed 
individuals. If the serum contains antibodies, the addition of complement 
results in cytolysis that is visualized by staining, followed by microscopic 
evaluation. Th e frequency of positive reactions (i.e. % of panel-reacting 
antibodies) gives an indication of potential local organ donors with whom 
the patient would cross-match positively. Modern tests, such as fl ow cy-
tometry and Luminex®, are able to measure these antibodies with increased 
sensitivity. Transplantation in the presence of donor-specifi c antibodies is 
associated with a high risk for acute rejection. Th is risk depends also on 
the titer of these antibodies. Lower titers might only be detected by the 
more sensitive techniques. (Fuggle, 2008) Th us, the clinical practice is to 
transplant patients with a negative cross-match, but in certain cases donor-
specifi c HLA antibodies can be generated also aft er transplantation. Th ere 
is robust evidence linking these donor-specifi c antibodies to the pathogen-
esis of chronic rejection. Th e histological hallmark is the detection of the 
diff use deposition of a fragment of complement C4d in peritubular capil-
laries, in addition to the classical features of chronic rejection.(Racusen, 
2006) Evidence was fi rst presented in 2001 when biopsies from 38 patients 
with features of chronic rejection showed a positive staining for C4d, and 
88% of them had donor-specifi c antibodies in their serum. (Mauiyyedi, 
2001) 
2.3. Acute rejection (AR) is a major determinant of both short-term and 
long-term graft  survival. Already in 1994 it was pointed out that the graft  
half-life was signifi cantly diminished if AR occurred later than one year 
aft er KTX, but even when it occurred within the fi rst year, AR had also a 
negative eff ect. (Matas, 1994) Later, the impact of AR on CAN was com-
pared in two diff erent periods: 1984–1987 and 1991–1994. A reduction in 
the number of AR cases was interpreted as a decrease in chronic rejection 
from 31 to 14%, and the half-life of cadaver allograft  kidneys was prolonged 
from 9 to 11 years. (Matas, 1999) Repeated AR was also demonstrated to 
aff ect graft  survival negatively, and to be a risk factor for CAN. Th e half-life 
of graft s was reported to be shortened to 3.9 years if multiple AR occurred, 
compared to 16.9 years with no AR.(Ferguson 1994) 
In a more recent study, the graft  survival at 5 years had fallen to 52% if 
multiple episodes of AR occurred, vs 85% if there was only one episode of 
AR. Risk factors for multiple episodes of AR were early AR, severe AR, and 
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either delayed graft  function (DGF) or slow graft  function. (Humar, 2000) 
Th e eff ect of the timing of AR on graft  survival was re-evaluated in the 
present era of immunosuppressants. In a study published in 2003 on 654 
KTX patients who were followed up for 10 years, early AR had a less nega-
tive impact than late AR. 85% of graft s with early AR (i.e. within the fi rst 
3 mo) survived, compared to 45% of those with late AR (over 3 mo). Th e 
subset of graft s without AR had the best outcome: 94% at 10 years when 
deaths were censored. (Sijpkens, 2003) (Figure 1)
Figure 1. Kaplan-Meier graft  survival, censored for causes other than chronic rejection 
for transplants without AR (solid line), with AR within 3 mo (dashed line) and with 
AR aft er 3 mo (dot line). (Sijpkens, 2003)
Th ere is, however, some discrepancy in the literature on the negative im-
pact of early AR on death-censored graft  failure or CAN, especially when 
more recent studies are included. (He, 2004) In the era of modern im-
munosuppression, not only the number but also the severity of AR has 
been successfully reduced. Th ese improvements have been linked with the 
use of tacrolimus, MMF and induction therapies. (Pallardo Mateu, 2004) 
However, sensitization, HLA mismatches, prolonged cold ischemia times, 
and kidneys from older donors still represent risks for AR and subsequent 
chronic renal allograft  dysfunction (CRAD).
17
2.4. Sub-clinical acute rejection (SAR). It has been known for a long time 
that biochemical monitoring of kidney function poorly refl ects histologi-
cal fi ndings. Th e necessity to understand the mechanism behind CAN was 
the rational for obtaining biopsies from well functioning kidney allograft s, 
hereaft er called protocol biopsies. In a series of 70 protocol biopsies from 
31 patients with stable kidney function obtained at one, two and three 
months post transplantation AR was diagnosed in 30% of the patients, the 
condition being named SAR. (Rush, 1994) SAR may represent either the 
evolving or the resolving phase of an alloimmune response. Under-diag-
nosed AR might be a risk factor for CAN, and this hypothesis was tested 
in a randomized control trial. Patients were biopsied by protocol during 
the fi rst year aft er transplantation. SARs were treated with steroid pulses in 
the treatment arm, whereas the other arm was simply observed. Aft er two 
years’ follow-up the treated group developed less AR, had lower chronic 
tubulointerstitial scores at 6 months, and lower levels of serum creatinine.
(Rush, 1998) Th us far these results have not been reproduced by any other 
group in a larger scale. 
Th e reduction in the AR rate with MMF, prednisone and CsA micro-
emulsion was not associated with a decreased incidence of SAR, although 
the great majority of the cases were mild.(Nickerson, 1999) Th e prevalence 
of SAR decreases over time from transplantation onwards, varying from 
25 to 60% at one month, 10 to 45% at three months and 8 to 18% at one 
year.(Kee, 2006) Th e great diff erences in the rate of SAR between institu-
tions are explained by diff erent immunosuppressive regimens, and by and 
the variable immunological risk of the population considered. (Nankivell, 
2006) Th e early risk of SAR is infl uenced by HLA mismatches and prior 
AR. (Choi, 2005) Th e protocol biopsy policy aimed at detecting SAR has 
been questioned in a series of mainly living donor transplants treated with 
antilymphocyte induction, tacrolimus and MMF, in which the rate of SAR 
was only 2.6%.(Gloor, 2002) It thus appears that SAR implies a certain de-
gree of immunoactivation, and if no therapeutic options are considered, 
SAR may lead to CRAD, CAN and fi nally reduced graft  survival. Although 
there is no consensus on the treatment of SAR with steroid boluses, some 
authors have suggested that the level of immunosuppression be raised 
by replacing CsA with tacrolimus, or azathioprine with MMF, (Shishido, 
2003) or by increasing the doses of the maintenance therapy.(Kee, 2006) 
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3. Pathophysiology of CAN: 
Non-immune-dependent factors
3.1. Donor factors are associated with graft  outcome, in both living and 
cadaver donation. In a recent report on 248 living KTX, the donors’ age, 
systolic blood pressure, high cholesterol and decreased glomerular fi ltra-
tion rate (GFR) were associated with a lower recipients´ estimated GFR 
two years aft er transplantation. (Issa, 2007) Kidney volume, evaluated in 
living donor candidates by three-dimensional helical computed tomogra-
phy, correlated with donor gender and body size, and was associated with 
kidney function at two years. Interestingly, smaller donor kidneys were 
prone to episodes of AR. (Poggio, 2006) Th e latter fi nding was also des-
cribed in the case of cadaver donors, suggesting that low “nephron mass” 
aff ects the susceptibility to immuno-mediated injury. (Sanchez-Fructuoso, 
2001) Female sex of the donor has been associated with poorer graft  out-
come irrespective of the recipient’s sex, reinforcing the concept of an im-
balance between nephron supply and the recipient’s metabolic demands. 
(Zeier, 2002) Also a high donor/recipient age ratio was associated with 
graft  loss in an analysis of 20,309 cadaver kidney transplants in the USA. 
(Swanson, 2002) Th e donor’s cause of death was also considered to infl u-
ence early graft  function, and it seemed to be associated with the early 
up-regulation of the immune system. (Nyhof, 2005) A review of the cause 
of death among donors in 2006 kidney transplants in Finland revealed that 
accidental death is decreasing, and there is a rising trend to accept cadaver 
kidneys from donors aft er surgical procedures, cardiopulmonary resusci-
tation or coronary disease. (Kyllönen, 2005) Th ese factors, along with the 
higher age of the donors, are believed to adversely aff ect the prognosis of 
kidney allograft  in the long run.
3.2. Donor brain death triggers an autonomic storm and the release of 
infl ammation mediators. A vast majority of the data in this area comes 
from animal experiments. A study in humans was recently conducted to 
evaluate the cytokine gene expression in kidney biopsies obtained at organ 
procurement, aft er cold ischemia and aft er 30 min of reperfusion. Th e re-
sults were compared with biopsies obtained at the same time points from 
living donors. Tubular and glomerular expression of interferon-γ, TGF-β1, 
PDGF-β and interleukin-2, -6 and -10 were all signifi cantly increased in 
biopsies from cadaver donors compared to living donors. Th e early cy-
tokine stimulation was linked to a further stimulation of the immune re-
sponse and long-term kidney survival. (Kaminska, 2007)
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3.3. Both ischemia and reperfusion induce profound changes in the graft . 
Aft er ischemia, tissues suff er from a lack of oxygen and nutrients, and sub-
sequently metabolic waste products accumulate. Reperfusion, on the other 
hand, causes sudden oxygenation of the tissue, leading to the formation 
of free oxygen radicals. Th is may overwhelm the capacity of scavengers to 
deal with this excessive off er. Reperfusion implies that leukocytes invade 
the graft , releasing chemokines and adhesion molecules to recruit more 
infl ammatory cells that consequently propagate the damage. (Perico, 2004) 
A prolonged time of cold ischemia increases the risk for delayed graft  func-
tion, with a direct adverse impact on graft  survival. (Salahudeen, 2004) 
3.4. Delayed graft  function (DGF) is the term used to describe kidney al-
lograft  non-function immediately aft er transplantation. Th is lack of func-
tion is a consequence of ischemia-reperfusion injury and/or immunologi-
cal injury. It is of vital importance to diff erentiate DGF from other causes 
of lack of function, such as volume depletion, AR, disease recurrence, 
CNI-toxicity and vascular or urinary tract complications. Risk factors for 
delayed graft  function are cold-storage preservation, non-heart-beating 
donors; inotropic support, donor age over 55 years, marginal kidneys from 
diabetic or hypertensive donors, and the recipient’s hypovolemia. (Perico, 
2004, Peeters, 2008) Th e incidence on DGF varies between 4 and 50%. Un-
fortunately, in the literature there are many diff erent defi nitions of DGF 
that it diffi  cult comparisons between studies. (Yarlagadda, 2008) Patients 
with DGF are at increased mortality risk and hospitalization is prolonged 
as a consequence of their dependence on dialysis. DGF predisposes to both 
AR and CAN. It has been hypothesized that during DGF hidden foreign 
antigens are exposed to the immune system of the recipient. Th e addition 
of both DGF and AR has been suggested to predispose to CAN, aff ecting 
thereby graft  survival. (Peeters, 2008) Th ere are reports, however, on the 
negative impact of DGF on graft  survival independent of AR. (Shoskes, 
1998) A reduction in the nephron mass aft er the recovery from DGF has 
been suggested to be one of the most important variables for the develop-
ment of CAN. Despite the eff orts, there has not been a reduction of the in-
cidence of DGF in the recent years. Th e deterioration in the donors’ quality 
is a possible explanation for this observation.  
3.5. Sub-optimal immunosuppression could be the result of patient non-
compliance with the treatment or a desired maneuver. Th e patients are 
more susceptible to infections and malignancies as a consequence of the 
use of immunosuppressants. Transplantation across HLA barriers requires 
more potent immunosupression, increasing the occurrence of the above-
mentioned complications even further. Whenever potentially life threaten-
ing conditions are recognized, a change in immunosuppression regimen is 
mandatory to save the patient. Th e cessation of immunosuppression carries 
20
an inevitably high risk of graft  loss due to acute and/or chronic rejection. 
Overcoming non-compliance is also a great challenge for physicians. 
Numerous causes hide behind it, such as level of education, patient/physi-
cian relationship, side eff ects of the drugs, cost of the drugs, reimbursement 
policy, and inconsistency in the frequency of drug intake. A graft  loss rate 
secondary to non-compliance are seen in all solid organ transplantations. 
A study on cadaver as well as living KTX revealed that 8% of the graft s were 
lost due to the patients’ non-compliance with the treatment.(Matas, 2002) 
Risk factors for non-compliance were young age, non-Caucasian race, un-
married status and emotional instability. (Jindal, 2003)
3.6. Hypertension (HT) is a well known contributor to chronic kidney dis-
ease (CKD) in native kidneys and in kidney transplants as well. A number 
of studies including diff erent immunosuppression regimens and ethnolo-
gies have shown a negative impact of HT on graft  survival. HT is particu-
larly common among African Americans, in whom the prevalence of HT 
was 90% and it was usually poorly controlled. (Cosio, 1995) Th e majority of 
CKD patients suff er from HT prior to receiving a transplant, and in many 
of them it is cause of uremia. Th e number and dosage of hypertensive drugs 
frequently increases aft er transplantation. Pre-transplant HT is a strong risk 
factor for HT also aft er transplantation, and it may be generated by native 
kidneys. Other common causes of HT in KTX are the use of calcineurin 
inhibitors, particularly CsA, corticosteroids, transplant artery stenosis, and 
chronic renal allograft  dysfunction (CRAD). (El-Amm, 2006) Th e preva-
lence of HT is already high when graft  function is normal, but it increases 
signifi cantly if CRAD develops. Over 90% of the patients are hypertensive 
when their creatinine level is above 260μmol/L. (Budde, 1997) Corticoste-
roids have been considered to be a risk factor for HT, but at present they are 
not believed to be a major contributor to HT due to the rapid tapering of 
the doses. (Midtvedt, 2002) Outstanding evidence of the deleterious eff ect 
of HT on graft  survival came from the Collaborative Transplant Study, in 
which the systolic blood pressure of 55% of the patients was over 140 mm 
Hg one year aft er the transplant. Both systolic and diastolic blood pressures 
were identifi ed as subsequent predictors of graft  failure.(Opelz, 1998) For 
each 10 mm Hg increase in systolic, diastolic and mean blood pressure at 
one year aft er transplant, graft  survival was shortened by 15%, 27% and 
30%, respectively. (Mange, 2000) An association between HT and AR has 
also been described. In a review of 1505 charts from fi rst cadaver KTX pa-
tients with an immunosppression regimen based on CsA, there was no cor-
relation between HT and 2-year graft  survival in the absence of AR. On the 
contrary, the additive eff ects of AR and HT correlated negatively with graft  
survival. (Cosio, 1999) It is diffi  cult to determine whether HT enhances 
the risk of AR, or whether it is a consequence of AR. Th e hemodynamic 
eff ects of HT, including glomerular hypertension, plus the up-regulation 
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of TGF-β and major histocompatibility complex I and II, might explain its 
contribution to the pathogenesis of CAN.(Sanders, 1995)
It is well established that HT increases the risk for cardiovascular dis-
ease and death in non-kidney diseases. HT is also a cardiovascular risk 
in KTX. It is unlikely for obvious ethical reasons that prospective trials 
were to be conducted in which patients would be randomized into optimal 
or suboptimal HT control groups. Despite the eff orts to control HT, the 
task remains challenging. Th is was evidenced in an observational trial in 
which two groups of patients with blood pressure over or under 160/90 
mm Hg were followed up for three years. Although the targets that these 
authors considered satisfactory is far above the recommendations of the 
Joint National Committee 7, they were able to recognize an increase in 
creatinine level and more cardiovascular events in the subgroup with the 
higher blood pressure.(Raiss Jalali, 2007) Data from Th e Finnish Registry 
of Renal Diseases reported that during the period 2004–2006, a great ma-
jority (86%) of the KTX patients was on hypertensive drugs, but only 22% 
had a blood pressure under the 130/85 mm Hg threshold.
It is evident that graft  and patient survivals are enhanced if the patients’ 
blood pressure is controlled successfully. However, it is still unclear whether 
there are diff erences in the effi  cacy of the drugs prescribed to reach this 
goal. Calcium channel blockers are oft en considered the fi rst choice be-
cause they reverse the vasoconstriction caused by CsA, and ameliorate its 
nephrotoxicity. (Zhang, 2003) Some authors claim that these drugs can also 
reduce the risk for AR, (Cosio, 1999) although the results of a meta-anal-
ysis were confl icting.(Ladefoged, 1994) Th e drugs most commonly used 
to treat chronic nephropathies are angiotensin-converting enzyme inhibi-
tors (ACEi) and angiotensin II receptor blockers (ARB). In KTX patients, 
the renin-angiotensin-aldosterone system (RAAS) is stimulated by CsA, 
among others. Th e widespread use of RAAS blockade has been hampered 
by its side eff ects, such as hyperkalemia, anemia and decreased glomerular 
fi ltration rate (GFR). Th e benefi ts might nevertheless be overwhelming, 
such as a reduction of glomerular hypertension, a decrease of proteinuria 
and a lowered production of TGF-β. In experimental models, both ACEi 
and ARB slowed the progression of CAN when compared to calcium chan-
nel blockers.(Cruzado, 2008) In addition to the nephroprotection that these 
drugs provide, they are also drugs of choice when left  ventricular hypertro-
phy is present. Th ey may also improve arterial stiff ness, thus improving the 
cardiovascular risk factor profi le. (Agarwal 2007) Th ere are not, however, 
up-to-date suffi  ciently powered randomized trials to address an improve-
ment in graft  and patient survival provided by ACEi or ARB.
3.7. Dyslipidemia is a common fi nding in the kidney transplant popu-
lation, its prevalence being 30 to 80%. Th e reported variability relies on 
diff erences among patient populations in regard to genetics, obesity, im-
munosuppressive regimen, age, post-transplant diabetes mellitus (PTDM), 
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CRAD, and the presence of proteinuria.(El-Amm, 2006) Data from Th e 
Finnish Registry of Kidney Diseases on the incidence of dyslipidemia in 
KTX patients during the period 2004–2006 indicates that 75% of them had 
triglycerides under 2 mmol/L, 90% had HDL cholesterol over 1 mmol/L, 
81% had LDL cholesterol below 3 mmol/L and 64% had total cholesterol 
below 5mmol/L (www.musili.fi /smtr).
 Th e fact that kidney graft s are mainly lost to CAN and the patient’s 
death due to cardiovascular diseases, three key questions arise: Does dys-
lipidemia contribute to the progression of CAN? Is dyslipidemia involved 
in the cardiovascular deaths of transplanted patients to the same degree as 
in the normal population? Does treatment of dyslipidemia lower the risk 
of graft  loss? To address the fi rst question, there is evidence that hyper-
cholesterolemia is indeed a risk factor for CAN, particularly when linked 
to AR. (Isoniemi, 1994) Th e lipid alterations typically present in CKD are 
increased concentrations of triglycerides, LDL, lipoprotein (a), apo C III 
and oxidized LDL, and decreased concentrations of HDL and apo A-1.
(Crook, 2003) Studies in animals suggest that dyslipidemia might aff ect 
the kidney via infl ammatory pathways, involving the recruitment of ma-
crophages and monocytes. Macrophage infi ltration is usually accompanied 
by the activation of prosclerotic growth responses by mesangial cells, in-
cluding mesangial fi bronectin, platelet-derived growth factor, and TGF-β.
(Pawluczyk, 2000) Although animal experiments have provided abundant 
evidence on the association between dyslipidemia and CKD, such evidence 
is limited in humans. Th e potential role of lipoproteins in glomeruloscle-
rosis and other glomerular diseases is suggested by the accumulation of 
cholesterol, LDL and apo B in the glomeruli. (Samuelsson, 1994)Th ere is 
increased mesangial lipid deposition and enhanced expression of LDL re-
ceptors on mesangial and epithelial cells in patients with chronic glomeru-
lar diseases. (Takemura, 1993) Th e challenge in demonstrating that dysli-
pidemia is a primary risk factor for CKD is that it is usually linked to other 
cardiovascular risk factors, such as HT, diabetes mellitus or metabolic syn-
drome. A valuable contribution to elucidate this came up in the Helsinki 
Heart Study, in which patients with normal kidney function at the begin-
ning of the investigation developed an increase in creatinine levels if they 
had low serum HDL level and an LDL/HDL ratio under 3.2 aft er 5 years of 
follow-up. (Manttari, 1995) A similar eff ect was noted even in patients with 
established CKD, when the progression of kidney dysfunction was faster if 
HDL was low.(Hunsicker, 1997) In KTX, hypertriglyceridemia, high con-
centrations of VLDL and lipoprotein (a) were independent risk factors for 
CRAD.(Castello 2002)
Dyslipidemia-related nephrotoxicity prompted investigators to study 
whether drug treatment could slow down or abolish the progression of 
CKD. In a trial published in 2003, patients already on RAAS blockers were 
randomized to receive additionally atorvastatin or placebo. Proteinuria 
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was signifi cantly decreased and CKD did not progress in the atorvasta-
tin group, which were not achieved in the placebo group.(Bianchi, 2003) 
Th e addition of pravastatin in KTX patients under CsA, azathioprine and 
methylprednisolone based immunosuppression seemed to reduce the 
probability of AR.(Katznelson, 1996) Th is benefi cial eff ect was masked if 
azathioprine was replaced by MMF.(Kasiske, 2001) Positive results were 
also found in another randomized study in patients on CsA-based immu-
nosuppression, comparing the eff ect of fl uvastatin on AR. (Holdaas, 2001)
It is not clear whether the risk factors for cardiovascular disease in KTX 
are the same as those in the general population. KTX patients oft en have 
a decreased GFR; they are therefore CKD patients. An increase in creati-
nine of 80–100 μmol/L was found to double the risk for cardiac death, non-
cardiovascular death, and overall mortality in KTX patients. (Soveri, 2006) 
Uremia may modify the characteristics of lipid moieties, turning them 
into a more atherogenic variant.(Kasiske, 2000) Th e largest multicenter 
ran domized double-blind placebo-controlled study was the Alert trial.
(Holdaas, 2003) Its goal was to assess the effi  cacy of fl uvastatin in reducing 
cardiovascular events. Aft er 5 years of follow-up there was a 17% reduc-
tion in the occurrence of major events (cardiac death, non-fatal myocardial 
infarction or a coronary intervention procedure), although it did not reach 
statistical signifi cance. Cerebrovascular events and a composite endpoint 
of graft  loss or doubling of creatinine, occurred at the same rate in both 
the treatment and placebo arms. One of the limitations attributed to this 
study was the fact that one inclusion criteria was patients who still had a 
functioning graft  six months or more aft er transplantation, thus including 
also very old graft s. It is therefore possible that it was too late to reverse the 
trend of cardiovascular mortality in many of the patients. Th ere was also a 
14% crossover to fl uvastatin in the placebo group, which limited the evalu-
ation of the benefi ts of fl uvastatin in intention-to-treat analysis. All in all, 
despite the fact that there is not irrefutable evidence provided by human 
trials favoring the use of statins to diminish CAN and cardiovascular events 
in KTX patients, there is no reason to believe that the risk factors of these 
patients are less harmful than those of the general population. On the con-
trary, KTX population is a selection of patients who have been exposed for 
various periods of time to the metabolic disturbances involved in uremia. 
Furthermore, many of them have a sub-optimal allograft  function, in addi-
tion to the side eff ects of immunosuppressive drugs. A post-hoc analysis by 
the Alert Study Group showed that timing of the initiation of the lipid-low-
ering therapy had an impact on the frequency of cardiac deaths and non-
fatal myocardial infarction. Th e major benefi t was observed when the drug 
treatment was started 0 to 2 years aft er transplantation. (Holdaas, 2005)
Th ere are some benefi ts beyond lipid modifi cation, i.e. so-called “pleio-
tropic eff ects” which have been attributed to statins. Statins have been 
shown to improve endothelial function by reducing oxidative stress, thus 
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lowering cardiovascular risk.(Sorrentino, 2005) Statins may also lower 
the level of infl ammatory markers, such as C-reactive protein. Th is ef-
fect is enhanced when another lipid-lowering agent, ezetimibe, is added 
to the treatment. Th e decrease in the concentration of C-reactive protein 
is directly linked to the decrease in LDL cholesterol levels. In the light of 
present research, it is diffi  cult to elucidate the individual contribution of 
each factor to the cardiovascular risk. (Davidson, 2005)
A relative drawback in the use of statins in KTX is the pharmacoki-
netic interaction between CsA and certain statins because they share the 
metabolic pathway (CYP3A4). Th e result of this interaction is a potential 
increase in the plasma levels of the statin, possibly leading to rhabdomyoli-
sis. (Ballantyne, 2003) Th is interaction may subdue the use of statins. Th e 
Alert study, however, reported a safety profi le of fl uvastatin, because it does 
not share the same metabolic pathway with CsA.(Holdaas, 2003)
3.8. Post-transplant diabetes mellitus (PTDM) In KTX the onset of PTDM 
represents a threat to both the patient and to graft  survival (Jindal, 2000) 
as it augments their already increased cardiovascular risk.(Bostom, 2002) 
PTDM implies exposure to micro- and macrovascular complications, and 
raises medical costs. An analysis issued by the United Renal Data System 
disclosed a cumulative incidence of PTDM of 9.1% at three months, 16% at 
12 months and 24% at three years. Risk factors for PTDM included black or 
Hispanic ethnicity, male donor, increasing HLA mismatches, hepatitis C, 
body mass index (BMI) over 30 kg/m2 and use of tacrolimus. Th e relative 
risk for graft  failure was 1.63 and for death-censored graft  failure 1.46. Th e 
overall relative risk of death was 1.87. (Kasiske, 2003) A German study on 
253 KTX patients with a mean follow-up of 3.3 years reported a prevalence 
of PTDM of 17%. Recipient age was signifi cantly associated with PTDM, 
and there was a trend toward PTDM as BMI increased. In this study, nei-
ther an immunosuppressive regimen nor HLA mismatches increased the 
risk. (Schiel, 2005) Some authors have stated that tacrolimus is not asso-
ciated with a higher risk of PTDM in a corticosteroid-free treatment regi-
men.(van Hooff , 2006) In the literature, the prevalence of PTDM has been 
reported to vary from 2 to 54%. Th e reasons for this wide variation are: lack 
of consensus in the defi nition of PTDM, mixed results on both cadaver 
and living-donor transplants, the use and doses of corticosteroids, use of 
tacrolimus, an allocation policy regarding HLA mismatches, diff erences in 
the length of the follow-up, and the prevalence of hepatitis C. Also CMV 
infections have been associated with PTDM.(Hjelmesaeth, 2005) 
Special attention should be paid to the defi nition of PTDM as reported 
in the literature: from insulin dependency one week aft er transplantation, 
to insulin use at one or three months. Th e defi nition of PTDM merely 
according to insulin requirements rules out patients who can be treated 
with oral antidiabetic agents and diet, and those who fulfi ll the criteria of 
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diabetes mellitus based on the oral glucose tolerance test. Th is means that 
the PTDM incidence reported in the literature might be underestimated. 
Although the above-mentioned risk factors help to estimate roughly the 
probability of PTDM, the fasting plasma glucose concentration on the day 
of transplantation, and the oral glucose tolerance test on day 5 has been 
proposed to identify those at risk of PTDM. (Kuypers, 2008) Th e preva-
lence of impaired glucose tolerance (IGT) in KTX patients is even more ob-
scure. It is known that IGT is related to cardiovascular diseases (Heldgaard, 
2004) In a recent study in the Chinese population, the prevalence of IGT 
6 months aft er transplantation was 6.7%, and the risk factors for IGT were 
very similar to those described for PTDM.(Chan, 2008) Another obser-
vational study from Australia reported an IGT prevalence of 28.5% and a 
PTDM prevalence of 11% aft er 6.6 years of follow-up for patients who were 
not previously diabetic. (Armstrong, 2006) In a recent study of 347 Spanish 
KTX patients without diabetes before or aft er transplant, impaired glucose 
metabolism was detected in 31.8% of them. Th is included IGT (24.6%) 
and those with isolated impaired fasting glucose (7.2%).(Delgado, 2008) 
Th ese data further support the view that alterations in glucose metabolism 
are very common in KTX patients. An interpolation of the relationship 
between IGT or impaired fasting glucose and CAN might be justifi ed, but 
there is scanty data available to support this.
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4. Other causes of kidney allograft damage
4.1. Calcineurin inhibitors-related toxicity
Kidney transplant is susceptible to nephrotoxic drugs in a similar fashion 
as native kidney. Some nephrotoxic drugs, such as CNI, are commonly 
used as immunosuppressive agents in transplantation. CsA is capable of 
dramatically reducing the incidence of AR, which is the most relevant risk 
factor for CAN. However, an observation made already in 1978 directed 
attention to its nephrotoxicity.(Calne, 1978) Th is was confi rmed later by 
the fi nding that kidney function deteriorates in non-kidney-transplant pa-
tients subjected to a CsA regimen.(Bennett, 1996) CsA nephrotoxicity can 
be either acute or chronic (Figure 2). 
Acute nephrotoxicity is functional, and results from reduced kidney 
blood fl ow, increased vascular resistance of the aff erent preglomerular 
arterioles, and consequently reduced GFR. It is caused by an imbalance 
between vasoconstrictors and vasodilators, due to the increased activity of 
endothelin and angiotensin II accompanied by a reduction in the synthesis 
and secretion of nitric oxide from the endothelium.(Fellström, 2004) 
A common histological pattern is isometric vacuolization in proximal 
tubular cells. (Mihatsch, 1986) Th ese acute changes are reversible, how-
ever, if CsA is discontinued or reduced. Conversely, changes related to 
chronic CsA nephrotoxicity are not reversible. Th is condition is histologi-
cally characterized by striped interstitial fi brosis and arteriolar hyaliniza-
tion (Figure 3). It is believed to be mediated by several factors, such as, 
TGF-β, platelet-derived growth factor, fi broblast growth factor and tumor 
necrosis factor-α. (Khanna, 2002) Th e real prevalence of CsA chronic 
nephrotoxicity is diffi  cult to estimate because conventional tissue stain-
ing cannot diff erentiate the initial injury behind interstitial fi brosis. Th e 
term CAN therefore covers interstitial fi brosis that could be the result of 
immune mechanisms, but also the consequence of chronic CsA toxicity. 
(Grinyo, 2004) Th e paradox is that the demonstrated short-term benefi t of 
CsA via the reduction in AR rates is counterbalanced by its nephrotoxic-
ity. Th is in fact partially explains why improved long-term outcomes have 
been diffi  cult to achieve.
27
Figure 2. Classifi cation of CsA nephrotoxicity from a clinico-pathological context. 
(Morozumi . 2004)
Th e other widely used CNI, tacrolimus, has also proved to be nephrotoxic. 
(Pirsch, 1997) Several strategies to overcome this problem have been pro-
posed, such as either reducing the CNI exposure or discontinuing its use. 
Th is requires the introduction of some other non-nephrotoxic immuno-
suppressant; such as the mammalian target of rapamycin (m-Tor) inhibi-
tors, i.e. sirolimus and everolimus. Unfortunately, it was noted that the rate 
of AR increased when CsA was discontinued, although rejections were 
usually easy to treat. (Fellström, 2004) Th e experience gained from the in-
creasing use of m-Tor inhibitors in the recent years has revealed that these 
compounds are not free of nephrotoxicity, particularly when combined 
with CsA. (Morath, 2007) 
CsA is known as a drug with a narrow therapeutic window. Its adminis-
tration therefore requires constant monitoring in order to assure adequate 
immunosuppression and to avoid toxicity. Th e dosage of CsA has been 
initially based on mg/kg body weight, but the high incidence of adverse 
events has made it necessary to monitor drug exposure. Th is has been done 
over the years by testing the patient’s CsA concentration in blood before 
giving the morning dose (C0). In the early 1990s it was observed that the 
C0 is not reliable in predicting freedom from AR, and that the best phar-
macokinetic measure of CsA was the area under the time concentration 
curve (AUC0–12h). (Lindholm, 1993) Figure 4.
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Figure 3. CsA-related nephrotoxicity. (A) acute CsA toxicity evidenced by isometric 
vacuolization in proximal tubular cells. Hematoxin-eosin. Magnifi cation X 400. (B) 
chronic CsA toxicity evidenced by striped interstitial fi brosis. Magnifi cation X 100. 
In (C) CsA-related arteriolar hyalinosis, evidenced by the deposition of red pale 
homogenous material under the intima. Magnifi cation X 400. (B) and (C) stained with 
Masson trichrome
A
B
C
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Although they are accurate for evaluating CsA exposure, the AUC0–12h 
measurements are not feasible for clinical follow-up. A great proportion of 
the variability of AUC0–12h was detected during the fi rst 4 h. Th e AUC0–4 also 
demonstrated a good correlation with drug exposure and freedom from 
AR.(Mahalati, 2001) Naturally, determination of the AUC requires multiple 
blood samples; a single time point measurement (more representative than 
C0) was therefore sought. Several studies have shown that the CsA blood 
concentration in samples taken 2 h aft er the morning dose (C2) correlated 
best with AUC0–4 (Mahalati, 2001; Jorga, 2004) and with the maximal im-
munosuppressive eff ect of CsA (measured by the inhibition of calcineurin 
in lymphocytes). (Halloran, 1999) Th e implementation of C2 monitoring 
in clinical practice was recommended in 2002, initially for de novo kidney 
transplants and for the maintenance phase thereaft er.(Cole, 2002) Numer-
ous studies have described the long-term benefi ts of switching from C0 to 
C2, such as better kidney function and reduced CsA doses. (Citterio, 2005; 
Dominguez, 2005; Th ervet, 2003, Pallardo, 2007) It was suggested that C0 
monitoring leads to the patients’ overexposure to CsA. (Di Paolo, 2004; 
Midtvedt, 2003) One of the limitations of C2 monitoring is the inability 
to detect toxicity in slow CsA absorbers, or to consider the increasing CsA 
absorption over time in the early post-transplant period. (Einecke, 2004) 
Despite the pharmacokinetic advantages of C2, there is no concensus 
on its targets at diff erent time points. Th e initially proposed C2 targets are 
Figure 4. Blood concentration-Time curves aft er CsA oral administration. Adopted 
from Wada, 2007
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continuously challenged downwards with the aim to avoid CsA nephro-
toxicity and to slow the progression of CAN. (Carstens, 2008)
4.2. Recurrent and de novo glomerular disease 
Chronic glomerulonephritis is the primary disease in 15 to 30% of KTX 
patients. As many of the primary diseases are systemic, they may recur in 
the graft . Data from the Finnish Registry for Kidney Diseases on the fre-
quency of primary disease in KTX patients are given in Figure 5.
Th e reported incidence of recurrent glomerulonephritis is around 10%, 
but there is great variability across institutions due to the diff erences in 
their biopsy policy regarding old dysfunctional graft s. Some diseases may 
recur soon aft er transplantation, such as atypical hemolytic uremic syn-
drome or focal and segmental glomerulosclerosis (FSGS). Others, like IgA 
nephropathy, tend to recur late. Th e data of the British Register of Kidney 
Diseases indicate that IgA nephropathy is the most common recurrent dis-
ease (ca 30% of all cases), and FSGS ranks second (ca 10% of all cases). 
(Furness, 2002) 
Membranoproliferative glomerulonephritis type1 tends to recur in 
25–50% of the patients, type 2 being much more frequent, with a rate ex-
ceeding 80%. Graft  loss due to recurrence occurs in 15–30% of the cases 
at 5 years. Idiopathic membranous glomerulopathy also tends to recur in 
10% of the patients, but it should be diff erentiated from secondary causes 
(viral infections and malignancy) and from de novo disease. (Choy, 2006) 
As kidney graft  survival has improved, also diabetic nephropathy can de-
velop in the allograft  in the long term if the patient’s glucose control is not 
satisfactory.
4.3. Viral Infections 
Th e most common infection aff ecting the post-transplantation period is 
by far caused by cytomegalovirus, and in the past decade BK polyoma 
virus (BKV) infection have been more frequently diagnosed. Transmis-
sion of BKV occurs during childhood via oral or respiratory tracts. Over 
80% of adult population is seropositive, but the virus remains latent in the 
renourinary tract. BKV replicates if the patient receives excessive immu-
nosuppression. (Egli, 2007) BKV associated nephropaty is histologically 
characterized by an exacerbated infl ammatory response of monocytes, 
polymorphonuclear and plasmacytoid cells, with a cytophatic eff ect and 
severe tubular injury, oft en mistaken for AR. Viral DNA may be detected 
in blood by polymerase chain reaction (PCR), but when there is suspicion 
of pathology, the diagnosis should be confi rmed by the presence of BK vi-
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Figure 5. Annual incidence of primary diseases of KTX patients per 1 million popula-
tion in 1965–2007. Adopted from www.musili.fi /smtr.
rus in the graft , revealed by immunohistochemistry. Polyoma nephropathy 
has an ominous prognosis, and decreasing immunosupression is an essen-
tial part of the treatment. (Blanckaert, 2006)
Virus-specifi c serology is used to stratify the risk for CMV-developing. 
Th e CMV seronegative recipients receiving a KTX from a positive donor 
are at the highest risk for CMV replication and disease. Th e risk also in-
creases in seropositive CMV recipients with T-cell and/or B-cell depleting 
antibody treatment for induction or rejection. (Egli, 2007) Th e patients at 
higher risk for developing CMV disease receive either prophylactic or pre-
emptive treatment. Th is policy reduced signifi cantly CMV disease. How-
ever, when prophylaxis ends there is still a risk for virus replication. CMV 
identifi cation in blood does not mean tissue invasion. Antiviral therapy is 
aim at eliminating viral replication to prevent CMV-disease. During the 
acute phase of cytomegalovirus infection, the kidney function may be af-
fected, but persistent infection is associated with poor graft  and patient 
survival. (Fishman, 1998) Persistent CMV infection in the graft  stimulates 
infl ammatory cells, which augment the production of several growth fac-
tors and cytokines. (Helanterä, 2006) Th e relation between cytomegalo-
virus and CAN has been the object of numerous studies. Th e results of a 
study on protocol biopsies suggested that a history of both previous AR 
and cytomegalovirus infection was associated with increased graft  vascu-
lopahty. (Helanterä, 2005)
A summary of the pathophysiological factors involved in CAN are de-
picted in Figure 6.
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Figure 6. Pathophysiological factors involved in CAN. Factors whose pathogenic role 
in CAN are controversial or are lacking of robust evidence are displayed with * 
Prolonged CIT
Marginal donor
Ischemia/Reperfusion
DGF
Early*
Late
Mild*
Moderate or severe
Repeated episodes
Sole episode*
Low immunosuppression
CMV*
Polyoma virus*
PTDM*
Hypertension
Dyslipidemia*
Untreated SAR*
HLA-mm*
AR
Hemodynamic disturbance
Metabolic disturbances
CNI-toxicity
Previous sensitization
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5. Diagnosis of kidney allograft damage
5.1. Classifi cations in kidney transplant pathology: 
Chronic allograft damage index
Th e term chronic allograft  damage index (CADI) was fi rst proposed in 
1992 (Isoniemi, 1992). It emerged as a necessity to discriminate histologi-
cal fi ndings two years aft er transplantation between four groups of patients 
undergoing diff erent immunosuppressive regimens. Th e utility of this clas-
sifi cation to predict chronic allograft  rejection was reaffi  rmed in 1994 by 
the same authors (Isoniemi, 1994). Th e CADI score is a number generated 
by the sum of six individual scores, each graded from 0–3. Th ese indi-
vidual parameters are infl ammation, interstitial fi brosis, tubular atrophy, 
mesangial matrix increase, intimal proliferation of the vessels and glomer-
ulosclerosis. Th e CADI score ranges from 0 to a maximum of 18. Details 
on individual scoring are depicted in Table 1 and Figure 7.
Later on in a multicentre trial, CADI was proposed as a suitable sur-
rogate marker of long-term graft  survival (Yilmaz, 2003). In that study 621 
protocol biopsies were obtained at baseline and at one and two years of 
follow-up, the CADI score progressed from the baseline to the end of fol-
low-up, demonstrating a deterioration in histology. Patients with a CADI 
score under 4 had normal creatinine levels, and aft er a 3-year follow-up 
only 4.6% of the graft s were lost. Conversely, a CADI score above 4 was 
linked to an increased creatinine level, and 16.7% of the graft s were lost in 
this period.
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Table 1. Individual scoring of CADI. (Isoniemi, 1994)
Infl ammation (focal/diff use)
0 no or trivial infl ammation
1 up to 25% of parenchyma infl amed
2 26–50% of parenchyma infl amed
3 >50% of parenchyma infl amed
Interstitial fi brosis (focal/diff use/subcapsular)
0 no fi brosis
1 up to 25% of the interstitium aff ected
2 26–50% of the interstitium aff ected
3 >50% of the interstitium aff ected
Tubular atrophy
0 no tubular atrophy
1 tubular atrophy up to 15% of proximal tubules
2 tubular atrophy in 16–30% of proximal tubules
3 tubular atrophy in more than 31% of proximal tubules
Mesangial matrix increase
0 no mesangial matrix increase
1 up to 25% of non-sclerotic glomeruli aff ected (at least moderate)
2 26–50% of non-sclerotic glomeruli aff ected (at least moderate)
3 >50% of non-sclerotic glomeruli aff ected (at least moderate)
Intimal proliferation (changes seen in at least 1 artery or 3 arterioles)
0 no intimal thickness
1 intimal thickness up to 25% of the remaining lumen
2 intimal thickness 26–50% of the remaining lumen
3 intimal thickness >50% of the remaining lumen
Sclerosis (increase in extracellular matrix, sclerotic areas positive stained with PAS)
0 no changes
1 <15% of glomeruli aff ected
2 16–50% of glomeruli aff ected
3 >50% of glomeruli aff ected
Th e CADI score has also been used to classify implant biopsies (Leh-
tonen, 2001). In this cohort the mean CADI score increased from 0.7 in 
implant biopsies to 2.9 aft er one year. It was also shown that patients with 
normal serum creatinine at one year nevertheless had an increased CADI 
score (2.5 ±1.5), reaffi  rming that histological changes might take place 
even in well functioning graft s. 
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Figure 1. Photomicroghraphs of four kidney biopsies showing a rising CADI score. 
(A) a 6-month protocol biopsy with normal histology, score: 0. (B) a 6-month 
protocol biopsy, score: 2, comprised of chronic vasculopathy (cv 1, not shown in the 
photomicrograph) and glomerulosclerosis. (gs 1) (C) a 6-month protocol biopsy, score: 
4, comprised of interstitial fi brosis (ci 1), tubular atrophy (ct 1), mesangial matrix 
increase (mm 1) and glomerulosclerosis (gs 1). (D) a 12-month protocol biopsy, score: 
8, comprised of interstitial fi brosis (ci 1), tubular atrophy (ct 1), infl ammation (i 1), 
glomerulosclerosis (gs 2) and severe chronic vasculopathy (cv 3). Masson’s trichrome. 
Magnifi cation X 100.
5.2. Classifi cations in kidney transplant pathology: 
Banff: terminology and its evolution over time
Th e Banff  classifi cation was created in a meeting held in Banff , Canada, 
in August 1991 and published in 1993. Th e Banff  Working Classifi cation 
of Renal Allograft  Pathology is a schema developed to standardize the in-
terpretation of kidney allograft  pathology across frontiers. Banff  ’97 is the 
most commonly used classifi cation system in the literature on KTX. De-
tails of the Banff  ’97 classifi cation are shown in Table 2. 
A B
C D
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Table 2. Banff  ’97 diagnostic categories for renal allograft  biopsies. (Racusen, 1999)
1. Normal
2. Antibody-mediated rejection, demonstrated to be due, 
 at least in part, to antidonor antibody.
A. Immediate (hyperacute)
B. Delayed (accelerated acute)
3. Borderline changes suspicious for acute rejection. Th is category is used 
 when no intimal arteritis is present, but there are foci of mild tubulitis
 (1 to 4 mononuclear cells/tubular cross section) and at least i1
4. Acute/active rejection
 Type (grade) Histopathological fi ndings
 I A Cases with signifi cant interstitial infi ltration (>25% 
of parenchyma aff ected) and foci of moderate tubu-
litis (>4 mononuclear cells/tubular cross-section or 
group of 10 tubular cells)
 I B Cases with signifi cant interstitial infi ltration (>25% 
of parenchyma aff ected) and foci of severe tubulitis 
(>10 mononucear cells/tubular cross-section or 
group of 10 tubular cells)
 II A Cases with mild to moderate intimal arteritis (v1)
 II B Cases with severe intimal arteritis comprising >25% 
of the luminal area (v2)
 III Cases with transmural arteritis and/or arterial fi bri-
noid change and necrosis of medial smooth muscle 
cells (v3 with accompanying lymphocitic infl amma-
tion)
5. Chronic/sclerosing allograft  nephropathy
 Grade Histopathological fi ndings
 I (mild) Mild interstitial fi brosis and tubular atrophy without 
(a) or with (b) specifi c changes suggesting chronic 
rejection
 II (moderate) Moderate interstitial fi brosis and tubular atrophy (a) 
or (b)
 III (severe) Severe interstitial fi brosis and tubular atrophy and 
tubular loss (a) or (b)
6. Other Changes considered not to be due to rejection.
Subsequent meetings have been held every other year to refi ne the clas-
sifi cation. Th e modifi cations to the Banff  schema made in 1997 synthe-
sized two diff erent classifi cation systems: Banff  ’95 and the classifi cation 
developed by CCTT (Collaborative Clinical Trials in Transplantation) 
(Racusen,1999) Th e earliest versions of the Banff  classifi cation emphasized 
the diagnosis of AR, mainly because this was the most common problem 
in those days. CAN was graded into three categories – mild, moderate or 
severe – without an attempt to determine the pathophysiological mecha-
nisms involved in this entity. Th e improvements in immunosuppressive 
regimens dramatically reduced the incidence of acute rejection, exposing 
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the problem of chronic allograft  damage. Th e elucidation of the role of 
donor-specifi c antibodies, suggested by C4d staining (see below) caused a 
revolutionary modifi cation of the Banff  classifi cation, and led to the omis-
sion of the general term “chronic allograft  nephropathy”.(Solez, 2007) In an 
attempt to discriminate the underlying processes, the present recommen-
dation distinguishes acute and chronic antibody-mediated rejection from 
acute and chronic T-cell mediated rejection. Unspecifi c interstitial fi brosis 
and tubular atrophy (IFTA) are now a separate category, graded from mild 
to moderate and severe. 
5.3. Protocol biopsies
Protocol biopsies are the standard of care in many transplant centers 
around the world, but the majority of the units avoid taking a biopsy from 
a well functioning graft . Th ere is no consensus regarding the possible bene-
fi ts that might justify the risks related to this practice. Numerous reports 
have shown that the risks for major complications, such as bleeding, ma-
cro scopic hematuria with ureteric obstruction, peritonitis or graft  loss, are 
only approximately 1%. Th e rate of minor complications resolving without 
intervention, such as asymptomatic arteriovenous fi stula, gross hematu-
ria, perirenal hematoma or vasovagal reactions, has been reported to vary 
between 0.5 and 7.3%. (Furness, 2003; Schwarz, 2005) Th e overall graft  
loss rate in fi ve studies reporting complications aft er protocol biopsies was 
only 0.03% and patient survival was 100%. (Furness, 2003; Schwarz, 2005) 
It is safer to take a biopsy by protocol than obtaining a biopsy of an in-
fl amed graft . As bleeding is the major concern connected with this proce-
dure, needles of diff erent thicknesses used for the biopsies were compared. 
(Schwarz, 2005, Nicholson, 2000) It was found that 14-gauge needles were 
associated with more pain, but the samples were more representative, com-
pared to samples taken with 16- or 18-gauge needles. Th e authors agreed 
that the 16-gauge needle was the best choice for the procedure, due to the 
low complication risk and adequate size of the sample.
A group of experts met in Boston in 2007 to discuss their experiences 
on protocol biopsies.(Mengel, 2007) Th ey concluded that there is suffi  cient 
evidence from clinical studies confi rming that protocol biopsies taken dur-
ing the fi rst six months aft er transplantation provide information that can-
not be obtained in any other way. Th e morphological and ultrastructural 
changes correlated with later graft  outcome. Th e best argument favoring 
protocol biopsy is that it is in fact the only tool for diagnosing SARs. Th e 
occurrence of SAR is high during the fi rst year, decreasing notably aft er-
wards. Th e policy of taking protocol biopsies with the intention of diagnos-
ing SAR, and possibly altering the treatment is therefore justifi ed during 
the fi rst six months. Protocol biopsies taken at one year from transplanta-
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tion reveal more chronic changes, although SAR might also be present, 
being a marker of a poor prognosis. (Nankivell, 2004) 
Variations in histological grading of kidney biopsies due to the high in-
terobserver bias, have aroused concern in the transplant community. (Fur-
ness, 2001) Unfortunately, if histological classifi cation is understood in dif-
ferent ways by diff erent pathologists, there is a great risk for heterogeneity 
in decision making.(Furness, 2003) Th e area of the cortex aff ected by in-
terstitial fi brosis can be scored with a computer-based image. Th is method 
has been proposed to facilitate scoring and to lower the great interobserver 
variation.(Servais, 2007) Even so, the reproducibility of these techniques 
can be hampered by diff erences in tissue fi xation, section thickness, levels 
of microscope light, and arbitrarily set thresholds. (Mengel, 2007)
Protocol biopsies are regarded fully justifi ed under certain circum-
stances, such as delayed graft  function, high-risk cross-match-positive 
patients, ABO-incompatible transplants, and as a surrogate of late graft  
dysfunction in clinical trials. (Nankivell, 2006) Th is group of patients is at 
increased risk for SAR, but other entities could also be diagnosed, such as 
CsA toxicity, polyoma nephropathy and recurrence of the original kidney 
disease. If such a strict protocol biopsy policy were to be applied, only a 
subset of patients would have a chance to be diagnosed accurately, and the 
SAR rate in the non-high-risk population would be uncertain. Protocol 
biopsies thus off er the possibility for a myriad of diagnoses, and help in 
understanding the physiopathological mechanisms involved in the early 
phases of pathological processes. Th ese fi ndings are time-dependent: early 
biopsies reveal more infl ammation, while later protocol biopsies reveal 
more CAN as well as many other pathological conditions.
5.4. Markers of kidney graft dysfunction
Th e degree of kidney dysfunction is the scale used to categorize patients 
with CKD into fi ve diff erent stages. (National Kidney Foundation 2002) 
Th e scale is based on GFR, usually estimated by formulas based on the 
serum creatinine level. KTX patients are considered by defi nition as carri-
ers of CKD, irrespectively of their GFR.(Levey, 2005) Th e equations used 
in non-KTX patients to calculate GFR do not necessarily perform equally 
well in KTX patients.(Gaspari, 2004) Despite the limitations of GFR es-
timates in KTX, they still remain the most simple and practical ways of 
monitoring graft  status. 
Th ere are diff erent methods of measuring GFR by using either exog-
enous or endogenous markers. Among the exogenous markers are inulin 
clearance, radioisotope clearance (i.e. 99mTc-labeled DTPA, 51Cr-labeled 
EDTA or 125I-labeled iothalamate) and nonradioactive contrast agent clear-
ance (i.e. cold iothalamate) (Poggio, 2007). Th e most commonly used endo-
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genous markers for predicting GFR are serum creatinine concentration and 
creatinine clearance. Although the methods based on exogenous markers 
are unquestionably more precise, they are laborious and expensive. Creati-
nine concentration is therefore the most commonly used marker of kidney 
function due to its simplicity, wide availability and low cost. However, the 
assay used for measuring creatinine concentration should be calibrated to 
avoid bias.(Stevens, 2007) Th e experience on non-transplant patients has 
shown that weight, muscle mass and extremes of age aff ect creatinine con-
centration independently of the GFR. Numerous formulas for predicting 
GFR that take in consideration anthropometric factors are thus proposed 
in the literature. Th e most used formulas are Cockcroft  and Gault, (Cock-
croft , 1976) and four-variable MDRD,(Levey, 2006) and Nankivell’s for-
mula has gained credibility in the transplant population. (Nankivell, 1995) 
All three formulas were compared with 125I-labeled iothalamate GFR in 
kidney transplant recipients. Th e four-variable MDRD equation performed 
the best, due to its lowest bias and highest precision. (Poggio, 2006) Never-
theless, an exogenous substance clearance should be used when a rigorous 
GFR measurement is needed, as for example in the assessment of renal 
function in living kidney donation. (Gaspari, 2004) Numerous studies have 
demonstrated that creatinine concentration does not predict pathological 
fi ndings in kidney biopsies. (Isoniemi, 1992; Nankivell, 2003) A signifi cant 
inverse correlation has been found between 99mTc-labeled DTPA and his-
tological changes, but 99mTc-labeled DTPA nevertheless underestimated 
the degree of histological damage. (Nankivell, 2003) 
Th e poor sensitivity to detect slight variations in GFR, together with 
several factors is infl uencing its concentration, make serum creatinine 
measurement for kidney function monitoring imprecise. Th erefore, the 
proposal in 1985 of another endogenous substance, cystatin C (CyC), to 
predict kidney function seemed promising. CyC is a low-molecular-weight 
protein produced at a constant rate by all nucleated cells. It is freely fi l-
tered through the glomerular membrane and completely catabolized in 
the proximal tubules. (Simonsen, 1985) However, a drawback was encoun-
tered later: also factors other than GFR infl uence CyC concentration, such 
as thyroid function,(Fricker, 2003) cancer (Kos, 1998) and glucocorticoid 
therapy.(Risch, 2001) An increased extrarenal excretion of CyC has been 
described when GFR decreases. (Sjöstrom, 2005) Others have suggested 
that it can also be aff ected by age, sex, body size, cigarette smoking, and 
C-reactive protein, independently of GFR. (Knight, 2004)
Th e fi rst extensive study of CyC performance in a cohort of 206 patients 
with various renal diseases concluded that CyC was more sensitive than cre-
atinine. (Newman, 1995) Aft erwards, two other large studies were carried 
out in a pediatric population. Th e authors presented a formula to estimate 
GFR from CyC, known as Bökenkamp and Filler formulas.(Bökenkamp, 
1998; Filler, 2002) A comparison of the sensitivity of CyC with creatinine 
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was extensively reviewed in a meta-analysis published in 2007. Th e authors 
pooled over 2000 patients from 24 studies with very diverse pathologies 
and a wide range of ages. Using GFR under 60ml/min as the defi nition of 
CKD, the analysis of accuracy favored CyC. Cut-off  values ranging from 0.9 
to 1.4 mg/L ruled out CKD. (Roos, 2007) A literature review published at 
the same time concluded that a large number of studies favored CyC over 
creatinine for the estimation of GFR, while many others had found no su-
periority of one over the other. (Zahran, 2007) One of the reasons proposed 
for the reported discrepancy in the accuracy of CyC to detect CKD was the 
diff erences in the clinical presentations. In 2005 a study of 460 individuals, 
including healthy controls, CKD patients and transplant recipients, showed 
that in transplant patients CyC was 19% higher at the same GFR level meas-
ured by 125I-labeled iothalamate clearance. A strong association between 
CyC and GFR was found in native CKD patients, and the authors proposed 
a new formula for GFR estimation, based on CyC. (Rule, 2006) A cohort of 
CKD patients was selected in another study in which the gold standard was 
51Cr-EDTA clearance. Th e study patients had CKD stages 2 to 3 (GFR 30–
89 ml/min/1,73m2). Th e authors concluded that CyC was a reliable marker 
of GFR in female patients with mild to moderate CKD. (Hojs, 2006) 
Th e impact of steroids on plasma CyC concentration is of great impor-
tance due to their wide use in transplantation. Th is was fi rst reported in 
an in vitro study using HeLa cells exposed to dexamethasone, revealing a 
dose-dependent increase in CyC concentration. (Bjarnadottir, 1995) Th e 
focus was therefore on the accuracy of CyC to predict GFR variations in 
the various circumstances that KTX patients go through. A prospective 
study on a case-control cohort undergoing diff erent immunosuppressive 
regimens, including patients requiring steroid boluses to treat AR, reached 
the same conclusion as the in vitro studies: glucocorticoids aff ected CyC 
concentration in a dose-dependent fashion. (Risch, 2001) CyC may thus be 
useless for monitoring GFR when the steroid dose varies, as it does in the 
treatment of AR.
Results from pediatric KTX have encouraged physicians to switch from 
creatinine to CyC in the monitoring of CKD. (Filler, 2008) In adults, how-
ever, the opinions are divided. A Canadian study of 198 patients classi-
fi ed by 99mTc-labeled DTPA into the fi ve CKD categories revealed that the 
Filler equation correctly classifi ed 76% of the patients, compared to 65% 
and 69% for the Cockcroft  & Gault and MDRD equations, respectively. 
However, in stage 4 CKD the Filler equation diagnosed correctly only 60% 
and the MDRD 93% of the cases. (White, 2007) Nine CyC-based equations 
and 14 creatinine-based equations were compared in a study in which GFR 
measured by inulin was analyzed in 103 adult kidney transplants. Th e con-
clusion was that CyC did not perform better than creatinine. Th erefore 
the authors do not justify the measurement of CyC for monitoring kidney 
graft  function.(Zahran, 2007) 
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Overall, there are no studies demonstrating that creatinine is superior 
to CyC in predicting GFR. On the other hand, several studies point to a 
higher accuracy of CyC in estimating GFR. At least in the adult popula-
tion, this supposed superiority of CyC seems to depend on the etiology of 
the kidney disease, the degree of impaired kidney function, and the use of 
steroids, among other factors.
5.5. Immunohistochemical techniques: TGF-β
Although not generally used in the routine analysis of kidney allograft s, 
immunohistochemistry opens a possibility for detecting precursors of 
structural changes, revealed later by light microscopy. Several injuries to 
the kidney are ultimately manifested as interstitial fi brosis, tubular atrophy, 
glomerular sclerosis and vasculopahty. Th e overexpression of transform-
ing growth factor β (TGF-β) plays an exclusive role in the fi nal pathway of 
interstitial fi brosis.
TGF-β is synthesized by all cells in the body as a large precursor that is 
cleaved intracellulary and secreted. It is stored in the extracellular matrix 
as a complex of TGF-β-propeptide and the TGF-β-binding protein. (Blobe, 
2000) Several factors can release TGF-β from this complex: alterations 
in pH, trombospondin 1, plasmin, and many other proteolytic enzymes. 
Th ree diff erent isoforms of TGF-β have been identifi ed in mammals: β1, 
β2 and β3. Th ey act as pleiotropic regulators of cell growth and diff eren-
tiation, angiogenesis and arteriosclerosis, immunosuppression, infl amma-
tion, carcinogenenesis and tissue repair. TGF-β1 acts as a major regulator 
of extracellular matrix production and degradation. (Pribylova-Hribova, 
2006) TGF-β1 can both stimulate and inhibit cell proliferation, playing an 
essential role in wound healing, as it restores the balance between infl am-
mation and matrix cell deposition following an injury. (Jain, 2000) It has 
also immunosuppressive eff ects: TGF-β1 promotes the diff erentiation of 
leukocytes and inhibits their proliferation and activation.(Letterio, 1998) 
Drugs can alter the production of TGF-β. Some drugs are of major im-
portance in kidney diseases, e.g., the calcineurin inhibitors CsA and tac-
rolimus are of particular interest due their wide use in KTX. Th ey are the 
most potent and well known inhibitors of calcineurin, a phosphatase en-
zyme involved in lymphocyte activation. CsA binds in the cytoplasm of T-
cells to cyclophillin, whereas tacrolimus binds to FK-binding protein. Th is 
complex activates calcineurin, which thereaft er binds to calmodulin in the 
presence of calcium. (Gooch, 2007)
Calcineurin inhibition not only reduces the production of interleukin 
2, but also aff ects other crucial molecules, such as other interleukins, nitric 
oxide synthetase, TGF-β, endothelin 1 and proteins involved in cellular 
protection against apoptosis. Particularly the increase in TGF-β production 
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is believed to be associated with CsA nephrotoxicity, although it may not 
be the only mechanism involved.(Cattaneo, 2004) Th e potential sources of 
TGF-β include macrophages, fi broblasts and tubular epithelial cells. It has 
been demonstrated that TGF-β expression is increased in kidney allograft s 
compared to normal kidneys. (Lantz, 1996) In patients undergoing CsA 
treatment, the increased TGF-β expression in the biopsies was associated 
with a more rapid decline in kidney function.(Cuhaci, 1999) Lowering of 
the CsA dosage decreased circulating TGF-β along with further improve-
ment in kidney function. (Hueso, 1998) CsA toxicity was found to be as-
sociated with a high intratubular expression of TGF-β. (Pankewycz, 1996) 
TGF-β showed a sustained increasing expression in sequential biopsies 
taken at implantation, one week aft er, and 6 months aft er transplantation. 
Th e authors noted that a history of delayed graft  function was related to 
TGF-β expression, and that both calcineurin inhibitors, i.e. CsA and tac-
rolimus, exerted a similar infl uence on it. (Jain, 2002) TGF-β was found 
to be increased in rats lacking the α-isoform of calcineurin, and this was 
proposed to be the cause of increased fi bronectin. It was thus suggested 
that the fi brosis and altered TGF-β expression associated with calcineurin 
inhibitors resulted from the inhibition of α-isoform of calcineurin activity. 
If so, targeted inhibition of the β-isoform of calcineurin may induce im-
munosuppression without nephrotoxicity. (Gooch, 2007)
Other widely prescribed drug families are the ACEi and ARB. A cross-
talk between the renin-angiotensin-aldosterone system (RAAS) and 
TGF-β has been highlighted recently.(Wolf 2006) Angiotensin II stimu-
lates TGF-β expression in the kidneys and also upregulates its receptors. 
Also angiotensin III and aldosterone can activate TGF-β. A key issue re-
garding nephroprotection is the blockade of RAAS with either ACEi or 
ARB. ACEi-use has been linked to reduced serum TGF-β levels, and via 
this mechanism, among others, to protect the kidneys. (Campistol, 1999) A 
pilot study demonstrated a decrease in TGF-β expression in kidney graft s 
aft er 12 weeks of treatment with losartan.(Mas, 2004) Th ere is no evidence, 
however, that ACEi or ARB can prolong graft  survival.
Th e search for molecular predictors of kidney graft  status in blood, 
urine or tissue has increased exponentially in recent years. Special atten-
tion was focused on AR, in the hope of fi nding a non-invasive method to 
diagnose this condition. Th is was achieved with quantitative PCR, detect-
ing increased mRNA for perforin and granzyme in the urine of patients 
with AR. (Li, 2001) Increased urinary excretion of the adhesion molecule 
sICAM-1 was observed in patients a few days before AR. (Teppo, 2001) In 
the light of these promising results, attention was subsequently directed at 
the possibility of diagnosing CAN by the detection of adhesion molecular 
excretion in urine. For example, the cleaved amino-terminal peptide from 
type III collagen (PIIINP) is secreted into the surroundings in the initial 
phases of interstitial fi brosis. A higher urinary PIIINP/creatinine ratio was 
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measured from kidneys with fi brosis, along with elevated concentrations 
of urinary TGF-β. (Teppo, 2003) Th ese fi ndings were associated with a 
poor kidney allograft  outcome. (Teppo, 2004)
Molecular techniques help to detect alterations at the molecular level, 
and their utility is not restricted to diagnostics, but they also have potential 
in the development of possible therapeutic targets. Although promising, 
these techniques cannot diff erentiate e.g. the type of rejection, or the cause 
of fi brosis. It is therefore unlikely that in the near future they can replace 
techniques based on histological morphology.
5.6. Microarrays
Genomic research has advanced remarkably aft er the development of 
microarray technology. Th e aim is to analyze simultaneous expression of 
tens of thousands of genes. Previously, the PCR technique made it pos-
sible to isolate individual genes. Microarrays open the possibility to iden-
tify simultaneous changes on multiple genes expression in diff erent phy-
siopathological processes. (Weintraub, 2006) 
Regarding AR, transcriptional RNA-microarray brought to light distinct 
molecular patterns that ultimately correlated with a response to treatment 
and to graft  outcome. Th e overexpression of genes involved in lymphocyte 
infi ltration and activation is linked to a worse prognosis compared to the 
up-regulation of genes involved in cell-cycling and proliferation.(Sarwal, 
2003) Th e gene expression of perforin, granzyme and FAS-ligand molecules 
diff erentiated biopsies, showing AR in control biopsies.(Scherer, 2003) In 
the case of CAN, there is wide up-regulation of genes involved in fi brosis, 
immune response and growth factors. However, these are hallmarks of late 
non-specifi c injury.(Hotchkiss, 2006) It is therefore challenging to stratify 
patients based on the mechanisms underlying the primary injury.
Th is new tool has several limitations.(Weintraub, 2006) Diff erent pat-
terns of gene expression from similar phenotypes have been found in indi-
vidual studies. Gene expression diff ers in the cortex and medulla, despite 
the same underlying process. Th us the size and representativeness of the 
sample is critical in the interpretation of the results. Microarray analysis 
does not provide information on proteins and metabolic processes, as post-
translational modifi cations can occur. In addition, the use of diff erent tools 
for data processing and statistical analysis may lead to diff erent conclu-
sions between studies. Overall, the microarray techniques look promising, 
but they are not widely available, and they require validation in large-scale 
randomized controlled trials.
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6. Aims of the study
Th e principal aim of this study was to fi nd risk factors involved in the pro-
gression of CAN and to analyze the accuracy of diagnostic methods for 
this entity.
To achieve this, the following secondary aims were set:
– to analyze the risk factors implicated in the progression of chronic 
histological kidney allograft  damage evolved from implant biopsies 
to six-month protocol biopsies (I);
– to fi nd histological markers able to predict kidney allograft  dysfunc-
tion during the fi rst two years aft er transplantation (I and II);
– to compare the prognostic value of two diff erent protocol biopsy 
policies (II);
– to compare the feasibility of the most commonly used estimates 
of kidney function, creatinine and cystatin C, for predicting CAN 
(III);
– to analyze the contribution of cyclosporin A concentration to CAN 
at the molecular level through the expression of a pro-fi brotic cy-
tokine, transforming growth factor β1 (IV)
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7. Material and methods
7.1. Patients
Altogether 553 patients living in the Helsinki University Central Hospi-
tal district received a kidney allograft  between June 1994 and April 2008. 
Adult KTX patients were followed up at the same hospital. Living KTX 
accounted for 2% of the total kidney transplants.
Th e Immunosuppressive regimen was modifi ed during the years, but 
the standard immunosuppression in this Institution is constituted by a cal-
cineurin inhibitor, an antimetabolite and methylprednisolone. Th e most 
commonly used calcineurin inhibitor was CsA. CsA dosing was based on 
blood concentration of the drug before the morning dose (C0). Th e target 
level at 1 month was 150–180 μg/L; at 3 months 120–150 μg/L; at 6 months 
100–140 μg/L and at 12 months and thereaft er 80–120 μg/L. If the case was 
a re-transplantation, with previous sensitization or a poor HLA match, CsA 
was replaced by tacrolimus. Also tacrolimus was the CNI of choice in case 
of rapid steroids-tapering or steroid-free regimen to be adopted. An early 
discontinuation of cortcosteroids was done if the patient developed severe 
complications related to its use, such as avascular necrosis of the femoral 
head or post-transplant diabetes mellitus. Aft er 2003, corticoste roids were 
discontinued aft er the fi rst year of transplantation. Azathioprine was the 
antimetabolite preferred up until to 2003, when it was replaced by MMF. 
Prior to 2003, MMF was however administered in selected cases by the 
physician’s discretion. Th e use of other medications believed to possibly 
aff ect the interpretation of the results, such as statins (Studies I and II) and 
antihypertensive drugs (Studies I, II and IV) was also recorded. 
7.2. Protocol biopsies
A protocol biopsy from the functioning kidney allograft s was obtained, 
with the patients’ full consent, if there was no medical contraindication 
for the procedure. Combined transplants (i.e. kidney-liver/ lung / heart / 
pancreas islets) were not considered for protocol biopsies. Before 2004, the 
policy at the Renal Division of the Helsinki University Central Hospital 
was to obtain a protocol biopsy at 6 months aft er transplantation. From 
2004 to September 2007 the policy changed to protocol biopsies obtained 
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at two time points: 3 and 12 months. Between June 1994 and June 2000, 
169 protocol biopsies were obtained at 6 months. Of those patients with 
representative material suitable for histological grading, 83 had an implant 
kidney biopsy available for comparison in Study I. Between December 
2001 and October 2005, 45 6-month protocol biopsies and 41 3–12-month 
protocol biopsies were obtained, constituting the material for Study II. For 
the purpose of this study, implant biopsies from 34 and 36 patients, respec-
tively, were available for comparison. 
A plasma sample obtained concomitantly with the protocol biopsy was 
preserved at -20 °C. A representative protocol biopsy and frozen plasma 
samples were available from 105 cases in 1996–2002. Th is constitutes the 
material for Study III. From October 2007 onwards a single protocol bi-
opsy has been taken at 6 months. Among the 112 out of 145 patients from 
whom protocol biopsies were obtained between 1 Jan. 2004 and 30 April 
2008, 49 had a successful measurement of CsA concentration taken 2 h (± 
15 min) aft er the morning dose. Th ese 49 patients constitute the material 
for Study IV. (Figure 8) 
7.3. Biopsy technique
Protocol biopsies were performed under ultrasonic guidance with either a 
Bard Magnum® or a Bard Biopty® automatic gun. An 18 gauge needle was 
used until 2007, and thereaft er 16 gauge needles were applied. According 
to the policy of this Hospital, two core samples were taken. One of them 
was embedded in either plastic or Historesin® (Leica Instruments GmbH, 
Heidelberg, Germany), while the other was sectioned for immunofl uores-
cence. Th e remaining tissue was frozen at -80 °C. Th e patients stayed in 
the Renal Ward for a mandatory 6 h of follow-up aft er the procedure, and 
before dismissal, an ultrasonic control was performed to screen for early 
complications. 
Implant biopsies were obtained either aft er revascularization during 
implantation or during organ harvesting. Th e device used was a Bard Mag-
num® automatic gun and 18 gauge needles. In this case the whole core sam-
ple obtained was embedded in paraffi  n.
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Figure 8. Total number of protocol biopsies obtained at diff erent time periods. 
Th e shaded areas represent the number of protocol biopsies selected for each study 
included in this thesis. Th e un-shaded areas represent the total number of protocol 
biopsies taken in that specifi c period
7.4. Histological analysis 
Implant biopsies embedded in paraffi  n were cut into several serial tissue 
sections and stained with hematoxylin/eosin, periodic Acid Shiff  (PAS) 
and Masson’s trichrome. Protocol biopsies embedded in either plastic 
blocks (until 2001) or Historesin and 3 μm thick serial tissue sections were 
stained with hematoxin/eosin, periodic Acid Shiff  (PAS), silver methen-
amine ( I–IV) and May-Grünwald-Giemsa (I) or toluidine (III) or Mas-
son’s trichrome (II and IV). C4d staining was routinely performed since 
2004 with immunoperoxidase, and since the beginning of 2008 with im-
munofl uorescence.
Both implant and protocol biopsies were scored by two observers ac-
cording to the CADI and Banff  ’97 classifi cations, described in detail else-
where. (Isoniemi, 1994; Racusen, 1999) Briefl y, interstitial infl ammation, 
interstitial fi brosis, mesangial matrix increase, tubular atrophy, vascular 
intimal proliferation, and arteriolar hyalinosis were scored semi-quanti-
tatively from 0–3 (0: none; 1: mild; 2:moderate; 3: severe) in both clas-
sifi cation systems. In CADI also the percentage of sclerotic glomeruli was 
scored from 0–3 (0: none; 1: <15% of glomeruli are slcerotic; 2: 16–50% 
of glomeruli are sclerotic, 3: >50% glomerulosclerosis). Banff  off ers a 
categorical classifi cation of CAN grades 1 to 3, whereas CADI scoring is 
based on the sum of the scores in six individual compartments (i.e., inter-
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stitial infl ammation, tubular atrophy, interstitial fi brosis, vascular intimal 
proliferation and percentage of sclerotic glomeruli) from a minimum of 
0 to a maximum of 18. Th e defi nition of AR was taken from Banff  ’97. 
Sub-clinical AR was defi ned as histological fi ndings compatible with AR or 
borderline AR in a a protocol biopsy from a patient whose graft  function 
was unaltered. Details of CADI and Banf´97 classifi cations are depicted in 
tables 1 and 2. 
Th e Banff  ´97 requires a minimum of 10 glomeruli and 2 arteries. Th e 
threshold for a minimal sample was defi ned as 7 glomeruli and 1 artery. In 
Study I the biopsies included for the analyses had a minimum of 5 glomer-
uli and three arterioli per slice. Th e mean number of glomeruli in protocol 
biopsies was 9,5, being the reason why in 2007 the needle used for the 
procedure was changed to 16 gauge. Th ereaft er, the adequacy of the biopsy 
was upgraded to 7 glomeruli. 
Th e Banff  classifi cation has evolved in the past decade, as described in 
5.2. Th e term CAN has now been replaced by chronic rejection or IFTA, 
when the chronic rejection criteria are not fulfi lled. Th e contemporary ver-
sion of the Banff  classifi cation was adopted in this Institution aft er 2008. 
At the time when the histological material for this thesis was collected, 
the Banff  ’97 version was used by renal pathologists. Th e term CAN is 
therefore used here in describing the results. CADI scoring system was 
extensively used in this thesis because its numerical stratifi cation allows a 
follow-up of the histological changes semi-quantitatively. Th e numerical 
diff erence in the CADI score obtained from sequential biopsies at diff erent 
time points (i.e. from implant to 3, 6 or 12 months) was assigned as delta 
CADI (ΔCADI) and used as a measure of progressing chronic histological 
damage in Studies I and II. 
Th e pathologists’ interpretation was passed on to the clinicians with the 
purpose of adjusting the medication and for assessing prognosis. Th e re-
maining histological material was preserved in the laboratory for further 
investigations. In Study IV, 49 preserved paraffi  n blocks were cut into 3 
μm thick slices for immunohistochemical analysis. Th ey were stained with 
rabbit polyclonal antibody against a peptide mapping at the C-terminus 
of TGF-β1 of human origin (Santa Cruz Biotechnology Inc., CA, USA, 
TGF-β1 (V): sc-146). TGF-β1 expression was scored semi-quantitatively 
from 0 to 3 in tubules, glomeruli, interstitial infl ammatory cells and ves-
sels by a single observer who was unaware of the medication or clinical 
status of the patients. Th e sum of the TFG-β1 in these compartments was 
acknowledged as TGF-β1 total score.
49
7.5. Clinical variables
Clinical data were obtained retrospectively from the patients’ hospital 
charts. Except for Study III, the data recorded were donor age and gender, 
donor type, donor’s cause of death (only in Study I), cause of end stage 
renal disease, dialysis modality (only in Study I), time on dialysis, number 
of HLA- AB and DR mismatches, percentage of panel-reactive antibodies 
(only in Study I), cold ischemia time (CIT), recipient’s race, gender and 
body mass index at the time of transplantation. During follow-up, the fol-
lowing data were recorded: occurrence of delayed graft  function (DGF, 
defi ned as the need for dialysis aft er transplantation), AR events, weight, 
blood pressure, infections requiring hospital admission (only in Study I) 
and particularly CMV infections. Th e rate of complications aft er protocol 
biopsies was specifi cally recorded in Study II.
7.6. Biochemical variables
Kidney allograft  function was estimated with serum (I) or plasma crea-
tinine (II–IV), 24-h creatinine clearance (I), serum cystatin C (III), esti-
mated glomerular fi ltration rate (GFR) based on creatinine (II and III) or 
CyC (III). For estimating GFR, creatinine expressed as μmol/L was con-
verted to mg/dl by dividing by 88.8. CyC was measured from the samples 
taken at the time of protocol biopsy, and preserved at -20° C. Th e method 
used for CyC determination was the particle-enhanced turbidimetric im-
munoassay (Dako Cytomation, Glostrup, Denmark). GFR was estimated 
using CyC, creatinine and their reciprocals, CyC-estimated GFR (Lars-
son equation: estimated GFR= 77.24 x CyC(-1.2623))(Larsson, 2004), Cock-
roft  & Gault (C&G=[(140-age) x weight] / (S-crea x 72) x 0.85 (if female))
(Cockcroft , 1976) and abbreviated Modifi cation in Diet in Renal Disease 
(MDRD=175 x S-crea (-1.154) x age (-0.203) x (0.742 if female) x (1.21 if black)) 
formulas (Morath, 2003). Glycosylated hemoglobin, total cholesterol, 
LDL-cholesterol, HDL-cholesterol and triglycerides were recorded (I and 
II). In addition, C-reactive protein, plasma albumin, 24-h proteinuria, 
parathyroid hormone, phosphorus and total calcium were collected (II). 
CsA concentration was obtained before the morning dose in Studies I, II 
and IV, and at 2 h aft er the morning dose in Study IV. CsA was measured 
with the enzymatic method (DiaSorin®). Also for the purpose of Study IV, 
mycophenolic acid concentration was measured at the time of the protocol 
biopsies (Cedia®). 
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7.7. Statistical analysis
Data are expressed as mean ± 1 SD, unless otherwise indicated. Th e Mann-
Whitney U test was used to assess diff erences in the rank distributions 
of continuous variables between two groups. Fisher’s exact test served to 
evaluate the relation between two binary variables. Correlations between 
histological classifi cations, individual scorings and other continuous va-
riables were calculated with the non-parametrical Kendall’s tau (I,III and 
IV) or Spearman’s test. Fisher’s exact test was used to correlate two binary 
variables (II). Diff erences between three groups were analyzed with the 
Kruskal-Wallis test, and the Dunn post-test was applied when considered 
convenient. Non-parametrical tests were used because of the relative small 
sample size and/or the lack of normal distribution of the variables (I, II, 
IV). CADI scores were transformed into binary variables using the mean 
value as cut-off  point for logistic regression analysis, and the odds ratios 
were calculated (I). Aft er testing for normality with the Kolmogorov-
Smirnoff  test, the t-test was applied to determine diff erences in GFR esti-
mates in patients with either low or high CADI scores (III). Recipient-op-
erator-characteristics (ROC) curves were used to compare the sensitivity 
and specifi city for predicting CAN with several creatinine- and CyC-based 
GFR estimates (III). Positive and negative predictive values were obtained 
for diff erent GRF estimates (III). Two-tailed P values lower than 0.05 were 
considered signifi cant. 
StatsDirect® statistical soft ware (version 2.2.4) was used in Study I. 
SPSS® statistical soft ware (versions 12.0, 13.0 and 16.0 for Windows, SPSS 
Inc., Chicago, IL, USA) and Excel 2003 (Microsoft  Corporation) were used 
for the calculations in Studies II, III and IV. ROC curves were calculated 
with Prism® statistical soft ware (version 4.0 Graph Pad Soft ware Inc., San 
Diego, CA, USA).
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8. Results
A total of 153 implant biopsies and 364 protocol biopsies were analyzed in 
this thesis. Because of the overlap in the time frame of individual studies, 
some of the biopsies were included in more than one investigation (Figure 
8). Th e percentage of living-related transplantation remained low across 
time (2%). Th e most common causes of end stage renal disease were dia-
betic nephropathy, chronic glomerulonephritis and polycystic kidney dis-
ease. Th e percentage of female donors was 45.5%, and female recipients 
constituted 36.5% of the patient population. Th e mean donor age was 45 
years (SD ±14) and mean recipient age 48 ±11 years. Th e mean total HLA 
mismatches varied slightly in these studies from 2. 07–2.3 (P=ns) and the 
mean number of mismatches was 2.2 ±0. 9. Despite the HLA-matching al-
location policy, CIT was relatively short and remained unchanged across 
the study periods (mean 20 ±4h). Th e percentage of patients with DGF 
increased considerably from 23% (I) to 37% (II and IV). (P=0.03). Th e 
age of the recipients increased over the years, from 48 to 52 years (P=ns). 
Recipients´ male sex has remained predominant, but its prevalence rose 
to 73% of the recipients in the latest study (IV). No major complications 
occurred aft er protocol biopsies, and both patients and graft  survival was 
100% aft er the procedure.  
8.1. Predictors of renal allograft histologic damage 
progression (I)
Biopsies at implantation retrieved from older donors and those died from a 
non traumatic cause had a higher CADI score. Predictors of a CADI score 
over 3 at 6 months were a CADI score over 1 at implantation, older age of 
the donor and higher number of HLA- AB mismatches. Patients who dis-
played moderate to marked progression of chronic histological changes in 
the 6 months following transplantation (ΔCADI) had a higher creatinine 
concentration at the time of hospital discharge. During the follow up, these 
patients had more elevate diastolic blood pressure than those who did not 
displayed deterioration on CADI score. A diastolic blood pressure over a 
cutoff  point of 85mmHg also predicted a higher serum creatinine during 
2 years of follow up. Th e total cholesterol and LDL cholesterol concentra-
tion at 6 months positively correlated with mesangial matrix increase. Th e 
HDL cholesterol concentration negatively correlated with vascular intima 
increase.
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Aft er testing CADI score components with logistic regression, using 
HLA-AB and HLA-DR mismatches, CIT, DGF, PRA, AR and serum creati-
nine at hospital discharge as independent variables, the risk for a ΔCADI 
over 1 was signifi cantly increased by the degree of glomerulosclerosis in 
donor biopsy and the high serum creatinine concentration at hospital dis-
charge. Th e odds ratios for having a ΔCADI over 1 are displayed in table 3.
Table 3. Odds ratio for high CADI score in implant biopsies and in 6 month biopsies 
and odds for a ΔCADI over 1
Odds ratio 95% Confi dence Interval
Odds for high CADI at transplantation
     donor age
     non-traumatic donor cause of death
1,07
3,89
1,01–1,14
1,13–13,33
Odds for high CADI at 6 mo
    CADI in donor biopsies
    Donor age, for 1-yr age increase
    HLA-mismatches, for 1-unit increase
3,82
1,05
2,36
1,19–12,21
1,01–1,10
1,09–5,10
Odds for a ΔCADI >1
    % gs at transplantation, for 1%-gs increase
    serum creatinine at hospital discharge, for
     1μmol/L  increase
1,10
1,01
1,02–1,19
1,00–1,02
8.2. Timing and value of protocol biopsies (II)
Twelve percent of 3 month protocol biopsies had chronic histological 
changes compatible with CAN. Th is percentage increased to 50% at 6 
months but was only seen in 34% of the biopsies at 12 months. Among the 
41 protocol biopsies diagnosed with CAN, only 4 of them were classifi ed as 
II b (2 at 6 months and 2 at 12 months), being the rest of the cases graded 
as I a. Th e changes in CADI scores between the donor and protocol biop-
sies and between protocol biopsies at diff erent time points are depicted in 
Figure 9. ΔCADI was negative in 19% of the biopsies between implantation 
and 6 months, 20% between implantation and 3 months, and 20% between 
implantation and 12 months. 
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Figure 9. Changes in CADI score between 
implantation, 3-, 6-, and 12 months biopsies
Borderline AR or subclinical AR were diagnosed in 7 biopsies. Th e con-
sequences of these fi ndings on patients’ management are depicted in table 
4. Patients with borderline or subclinical AR did not show higher CADI 
score at 12 months compared with those without these features. Th e esti-
mated GFR at 18 months was not signifi cantly diff erent among those with 
or without borderline or subclinical AR. CADI score at implantation, at 3-, 
6-, and 12 months negatively correlated with estimated GFR at 18 months, 
but ΔCADI did not. 
Steroids were withdrawn at one year aft er transplantation from 29 out 
of 45 patients in the subgroup of patients with 6 month biopsies and from 
22 out of 41 in the subgroup of patients with sequential 3 and 12 months 
biopsies. A single episode of late AR occurred in the fi rst subgroup, which 
was successfully treated with steroid boluses and conversion from CsA to 
tacrolimus.
54
Table 4. Consequences of protocol biopsies diagnosis on patients’ management
Patient no. and 
time of biopsy
Finding in 
protocol biopsy
Consequence 
of the biopsy
1. (3 months) Subclinical acute rejection Ia Control biopsy at 5 mo. with normal histology
2. (3 months) Subclinical borderline rejection Control biopsy at 6 mo. with normal histology
3. (3 months) Subclinical borderline rejection Control biopsy at 6 mo. with normal histology
4. (3 months) Tubular vacuolization Tacrolimus dose reduction
5. (6 months) Subclinical borderline rejection Ib Intensifi cation of immunosuppression
6. (6 months) Subclinical borderline rejection Conversion from cyclosporin to tacrolimus
7. (6 months) CAN
Conversion from 
azathioprine to 
mycophenolate
8. (6 months) CAN
Conversion from 
azathioprine to 
mycophenolate
9. (6 months) CAN
Angiotensin-converting-
enzyme inhibitor therapy 
(ACEi)
10. (6 months) CAN and interstitial infl ammatory infi ltrate
Control biopsy at 12 mo. 
with no  infl ammation
11. (12 months) Subclinical acute rejection Ia
Conversion from 
cyclosporin to tacrolimus 
and re-biopsy 1 mo later 
with normal histology
12. (12 months) Suclinical borderline rejection Control biopsy 1 mo later with normal histology
13. (12 months) CAN ACEi therapy, cyclosporin reduction
14. (12 months) CAN ACEi therapy, cyclosporin reduction
15. (12 months) CAN, suspicion of calcineurin inhibitor toxicity Cyclosporin dose reduction
16. (12 months) Infl ammatory infi ltrates Intensifi ed clinical follow-up
8.3. Sensitivity and specifi city of several estimates of GFR 
to predict CADI (III)
Creatinine, CyC and several formulas for estimating GFR that are based on 
these biochemical molecules were compared with kidney allograft  histo-
logy. CADI, interstitial fi brosis, chronic vasculopathy and tubular atrophy 
correlated signifi cantly with creatinine, 1/creatinine, MDRD, CyC, 1/CyC 
and the Larsson equation. Only creatinine and 1/creatinine correlated ad-
ditionally with CAN and chronic glomerulopathy.
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A subdivision of the biopsies using a CADI cutoff  point of 2 demonstrated 
that mild histological changes were best revealed by creatinine, although with 
modest sensitivity/ specifi city. A plasma creatinine threshold of 111 μmol/L 
distinguished 74% of the patients with CADI>2 and excluded this condition 
in 66%. In the case of CyC, a plasma concentration threshold of 1.12 mg/dl 
had a positive predictive value of 69% and a negative predictive value of 60%.
Th e ROC area under the curve for creatinine was 0.72 (p<0.001). Cre-
atinine and its reverse correlated best with CADI, chronic allograft  ne-
phropathy, chronic infl ammation, tubular atrophy, vascular changes and 
glomerulopathy. Neither the C&G nor MDRD formulas to estimate GFR 
improved the performance of creatinine alone. CyC and Larsson’s formula 
performed similarly (for both, the ROC area under the curve was 0.67). 
(Figure 10) 
Figure 10. Comparison of ROC curves using a CADI cutoff  point of 2. Crea: plasma 
creatinine; C&G: Cockcroft  and Gault, MDRD: Modifi cation of Diet in Renal Disease; 
CyC: cystatin C; Larsson: Larsson’s formula. 
8.4. Expression of TGF-β1 in protocol biopsies (IV)
8.4.1. TGF-β1 expression in protocol biopsies and its 
 relationship with CADI and exposure to CsA 
Neither TGF-β1 expression in diff erent compartments nor total TGF-β1 
diff ered signifi cantly among 3-, 6- and 12-month biopsies. Details of the 
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distribution of TGF-β1 in individual compartments at diff erent time points 
are depicted in Figure 11. Th e expression of TGF-β1 in interstitial infl am-
matory cells correlated positively with CADI specifi cally at 6 months (tau 
0.65 p=0.02). Th e only case of suspected acute CsA toxicity was diagnosed 
in a 6-month protocol biopsy, which displayed a considerable increase in 
TGF-β1 expression in all compartments. In this case C0 was, however, on 
target and C2 was 602 μg/L. Neither C0 nor C2 correlated with IFTA at 
any time point. Two cases of SAR or borderline AR were found, and they 
showed a remarkable increase in total TGF-β1 expression. (Figure 12) 
Th e daily dose of CsA correlated negatively with total TGF-β1 expres-
sion in 12-month biopsies. A negative correlation was also found between 
the daily dose of CsA and TGF-β1 expression in interstitial infl ammatory 
cells in 6-month biopsies (tau -0.66 P<0.01) and with TGF-β1 expression 
in glomeruli at 12 months (tau -0.42 P<0.01). Th e CsA dose in mg/kg cor-
related negatively at 6 months, both with TGF-β1 expression in interstitial 
infl ammatory cells (tau -0.75 P=0.004) and in tubules (tau -0.52 P=0.04). 
Figure 11. Mean TGF-β1 expression in 3-, 6- and 12-month protocol kidney biopsies 
in tubules (TGF-b T), glomerulus (TGF-b G), endothelium (TGF-b V), infl ammatory 
cells (TGF-b Infl ) and the sum of individual scores (TGF-b total)
C0 did not correlate with the expression of TGF-β1 at any time point. On 
the contrary, C2 correlated negatively with TGF-β1 expression in intersti-
tial infl ammatory cells at 12 months (tau -0.38 P=0.02). Patients whose 
C2 levels were below 600 μg/L at 12 months expressed more TGF-β1 in 
interstitial infl ammatory cells, but the signifi cance was borderline (P= 
0.058). When the C2 concentration was below 450 μgl/L at 12 months, 
more expression of TGF-β1 was detected in vessels (P= 0.043) and the total 
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score was elevated (P= 0.043). Th e expression was slightly elevated also in 
tubules (P= 0.08) and glomeruli (P= 0.059). 
Altogether 8% of the patients were treated with ACEi or ARB at 3 
months and 52% at 12 months. A separate analysis of all patients on ACEi 
/ARB compared with those not using these drugs did not reveal diff erences 
in TGF-β1 expression.
8.4.2. TGF-β1 expression in protocol biopsies and 
 kidney allograft function 
We observed that patients with any expression of TGF-β1 in interstitial in-
fl ammatory cells had a higher creatinine level at all time points compared to 
those without any expression of the growth factor. Th e diff erences reached 
statistical signifi cance only at 6 months (creatinine 110 vs 128 μmol/L, 
p<0.03). In other data points the signifi cance was borderline (at 1 month 
mean creatinine 124 vs 153 μmol/L, p=0.057; at 3 months creatinine 112 vs 
128 μmol/L, p= 0.08; at 12 months creatinine 115 vs 133 μmol/L, p= 0.07 
and at 2 years 122 vs 153 μmo/L, p= 0.051).
Figure 12. Photomicrograph of a 6-month protocol biopsy displaying features of SAR 
demonstrating TGF-β1 expression in tubules (arrowhead), glomerulus (thin arrow), 
infl ammatory cells (open arrow) and vascular wall (thick arrow). Th e total TGF-β1 
score was 9, composed of the sum of T3, G2, Infl 2 and V2. Indirect immunoperoxi-
dase. Original magnifi cation X 200.
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8.5. Summary of the histological results
8.5.1. Summary of CADI in protocol biospies. 
Th e mean CADI score in implant biopsies ranged from 0.6–1.35 (Studies 
I and II, respectively, P<.001). Absolute normal histopathology was found 
in 33% of the implant biopsies in Study I. Th e most common fi ndings in 
these biopsies were glomerulosclerosis (mean 3%), chronic vasculopahty 
(mean score 0.24), tubular atrophy (mean 0.25) and interstitial fi brosis 
(mean 0.51). Any degree of glomerulosclerosis ranged from 27–43% of 
the implant biopsies, and the mean percentage varied from 3–9% (Stud-
ies I and II, respectively). Chronic vasculopathy (i.e. arterial fi brointimal 
thickening) was found in 16% of the donor biopsies, on average. (Studies I 
and II). Arteriolar hyalinosis was a common fi nding at implantation (mean 
0.36, Study I). 
Th e mean CADI score in 3-month biopsies was on average 1.25. Ab-
solutely normal pathology was found in 31% of these biopsies, and CADI 
≤1 was observed in 73% of these biopsies. Th e most common fi nding was 
infl ammation (mean score 0.5), followed by interstitial fi brosis (mean 0.2) 
and tubular atrophy (mean 0.2). Less common were chronic vasculopathy 
(mean 0.18) and glomerulosclerosis (mean 0.1). Mean arteriolar hyalinosis 
was 0.15 (IV). Tubulitis was seen in three cases in Study II (two borderline 
AR and one SAR) and in one case of SAR in Study IV. On average, SAR and 
borderline AR were diagnosed in 5.5% of these biopsies.
Th e mean CADI score in 6-month biopsies fell from 3.27 in Study I 
to 2.2 in II and 1.55 in IV. (P=0.02) Th e lower CADI scores in Studies II 
and IV can be attributed to the lower scores of interstitial fi brosis (mean 
0.27–0.74), tubular atrophy (mean 0.27–0.74) and chronic vasculopathy 
(mean 0.33–0.60). Infl ammation was less common in the biopsies included 
in Study IV (mean 0.18) than in those included in Study II (mean 0.50). 
Mesangial matrix proliferation and chronic glomerulopathy were seldom 
observed. Th e mean arteriolar hyalinosis scores varied from 0.18–0.57 (IV 
and I, respectively). Tubulitis was seen in two cases in Study II and in one 
in Study IV. All studies taken together, SAR and borderline AR were de-
tected, on average, in 3.3% of the 6-month protocol biopsies.  
Th e mean CADI score in 12-month biopsies varied slightly from 1.9 
(Study II) to 2.2 (Study IV).(P=ns) Th e most common fi ndings were in-
fl ammation (mean 0.49), interstitial fi brosis (mean 0.44) and tubular atro-
phy (mean 0.37). Mean chronic vasculopahty varied from 0.1 (II) to 0.56 
(IV). Mesangial matrix increase or chronic glomerulopathy were seldom 
seen. Th e mean arteriolar hyalinosis score was 0.2. Mild tubulitis compa-
tible with borderline AR was observed in one case, in infl ammatory cells 
and more intense tubulitis compatible with SAR was observed in another 
case, constituting altogether an incidence of 3%.
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8.5.2. Summary of AR, SAR and immunosupression 
AR. In the population included in Study I the cumulative prevalence of 
AR was 36%. In Study II the incidence of AR was 8.,5% and in Study 4 it 
was 14%. More specifi cally, in Study IV the incidence of AR was 23% at 
3 months, 18% at 6 months and 8% at 12 months. Late AR (i.e. aft er 12 
months) was diagnosed in two patients in Study 1, in one patient in Study 
II, and in three patients in Study IV. SAR was found in 3 out of 83 (3.6%) 
6-month protocol biopsies in Study I. In Study II, SAR or borderline AR 
was detected in 3 out of 41 (7.3%) 3-month protocol biopsies, in 2 out of 
45 (4.4%) 6-month protocol biopsies, and in 2 out of 41 (4.9%) 12-month 
protocol biopsies. In Study IV, one case of SAR at 3 months and one bor-
derline AR at 6 months were observed out of 49 protocol biopsies (4%). 
Th e treatment of SAR or borderline AR was under physician discretion. 
Two patients in Study I were prescribed treatment for AR. Th ree patients 
in Study II and two patients in Study IV with SAR or borderline AR were 
switched from azathioprine to MMF or from CsA to tacrolimus. Four pa-
tients in Study II in whom immunosuppressive treatment was unchanged 
were later re-biopsied, and histology was normal in all of them. 
Patients’ immunosuppressive regimen varied across the years. Th e pro-
portion of patients on tacrolimus rose from 2.4% in Study I, to 10% in II 
and 23% in IV (P<0.0001). Th e use of MMF increased from 14.5% (I) to 
97.5% (II and IV), respectively (P<0.0001). Methylprednisolone was rou-
tinely used during the fi rst year aft er transplantation in 94% (I) to 100% 
of the patients (IV). An inhibitor of mammalian target of rapamacyn was 
used in only one patient (IV) aft er discontinuing CsA due to drug-related 
neurotoxicity.
8.5.3. CsA toxicity in protocol biopsies
In Studies I and III, no cases of either acute or irrefutable chronic histo-
logical CsA toxicity were identifi ed. In Study II, isometric vacuolization of 
proximal tubular cells compatible with calcineurin inhibitor toxicity was 
found in one 3-month protocol biopsy and one 12-month protocol biopsy. 
In Study IV, isometric vacuolization in proximal tubule cells and arteriolar 
hyalinization compatible with acute CsA nephrotoxicity was seen in one 
protocol biopsy. All in all, CsA nephrotoxicity was seldom seen in this se-
ries of protocol biopsies (0–2%). 
8.6. Summary of the progression of 
histological damage (ΔCADI) 
Progression of CADI from implant to 3, 6 and 12 months. Th ere was an 
increase of 0.7–1.2 (P=ns) in mean CADI from the time of implant to the 
3-month biopsies. Th is diff erence was caused by an increase in infl amma-
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tion (mean increase from 0 to 0.5) and interstitial fi brosis (mean increase 
from 0 to 0.2). A higher ΔCADI was observed when the time period was 
longer: from implant up to 6 months the mean CADI rose from 1.35 to 
3.27 in Study I (P<0.0001) and from 0.6 to 2.2 in Study II (P=ns). In these 
cases the diff erence was mainly due to interstitial fi brosis (mean increase 
from 0.5 to 0.74 in Study I and from 0 to 0.6 in Study II), tubular atrophy 
(mean increase from 0.25 to 0.74 in I and from 0.1 to 0.6 in II), increase in 
mesangial matrix (mean increase from 0.23 to 0.56 in I and from 0 to 0.3 
in II) and infl ammation (mean increase from 0 to 0.5 in II). A statistically 
signifi cant increase was observed in interstitial fi brosis (P=0.01), tubular 
atrophy (P<0.0001), mesangial matrix (P<0.0001), transplant glomerulo-
pathy (P=0.01) and CADI (P<0.0001) in Study I. Neither glomerulosclero-
sis nor chronic vasculopathy increased signifi cantly from implantation up 
to 3 or to 6 months.
Th e mean CADI score rose from 0.7 in implant biopsies to 1.9 in 
12-month biopsies. Th e diff erence was mainly due to interstitial fi brosis, 
tubular atrophy and infl ammation, although it did not reach statistical sig-
nifi cance. Th ere was no substantial increment in chronic vasculopathy or 
glomerulosclerosis from implant to the 12-months biopsies.
Progression of CADI from three to six and twelve months. Study II 
included sequential biopsies taken at 3 and 12 months. Also in Study IV 
sequential biopsies at these time points in a subgroup of 7 patients was 
included in the analysis. Th ere was a slight increase in CADI from 1.2 to 
1.9 (P=ns). Th e mean CADI increased from 1.31 at 3 months to 1.55 at 6 
months, and to 2.2 at 12 months (P=ns). Th is diff erence was mainly due 
to an increase in interstitial fi brosis (mean increase from 0.23 to 0.48), tu-
bular atrophy (mean increase from 0.23 to 0.44) and chronic vasculopathy 
(mean increase from 0.15 to 0.56). Th e diff erences in ΔCADI were not sta-
tistically signifi cant. Infl ammation was present to a varying extent at all 
time points, and therefore did not aff ect ΔCADI. 
8.7. Summary of the risk factors involved in the 
progression of CADI 
Th e risk factors for a high CADI in implant biopsies were donor age (odds 
ratio 1.07) and non-traumatic cause of donor death (odds ratio 3.89). Th e 
risk factors for a high CADI at 6 months were CADI in implant biopsies 
(odds ratio 3.82), donor age (odds ratio 1.05) and HLA-AB mismatches 
(odds ratio 2.36). Th ere were diff erences in the donor-related character-
istics included in Studies I, II and IV. Th e mean age of the donors rose 
from 41 years in Study I, to 48 years in Study II and 52 years in Study IV 
(P=0.023). Th e cause of death of the older donors was more likely to be 
61
of non-traumatic origin (e.g. a cerebrovascular accident), whereas a trau-
matic cause of death was more common among younger donors. Male sex 
of donors was prevalent in Study I, but the opposite was in the study in-
volving more recent transplants (IV) (P=0.023). 
Th e risk for a ΔCADI higher than 1 was elevated when glomeruloscle-
rosis was found in the implant biopsies, and also if serum creatinine con-
centration remained elevated at the patient’s discharge from hospital aft er 
transplant surgery. Either a 1% increase in glomerulosclerosis in donor 
biopsies or a 10 μmol/L increase in serum creatinine at hospital discharge 
aft er transplantation increased the risk of having a ΔCADI over 1 by 10%. 
Blood pressure and lipid profi le correlated with individual components 
of the CADI score. Total cholesterol and LDL cholesterol correlated posi-
tively with the increase in mesangial matrix. HDL cholesterol correlated 
negatively with the increase in chronic vascular changes. Triglycerides 
did not have an impact on the development of chronic histological lesions 
from implant to 6-month biopsies. Both systolic and diastolic blood pres-
sure correlated with tubular atrophy. Particularly diastolic blood pressure 
correlated with ΔCADI. Both systolic and diastolic blood pressure slightly 
fell aft er transplantation, in line with the increased number of patients un-
der hypertensive treatment. Regarding dyslipidemia, clearly higher LDL 
cholesterol was observed in the patients in Study I (mean 3.6 mmol/L at 
6 months) compared with Study II (mean 2.45 mmol/L) (P=0.001). Total 
cholesterol rose during the fi rst year aft er transplantation, decreasing af-
terwards. Triglycerides, on the contrary, decreased aft er transplantation, 
and HDL cholesterol increased slightly during the two years of follow-up 
(I). Over the years we observed a marked increase in the use of statins. In 
Study I only 8% were on drug treatment for dyslipidemia, and the percent-
age rose to 59% of the patients included in Study II. (P<0.0001) A similar 
trend was observed with antihypertensive drugs, particularly with ACEi 
and ARB, which were seldom used in Study I, rising to 14% at 6 months 
post-transplantation of the patients in Study II, and to 33% of the patients 
in Study IV. (P<0.0001)
In Study I the mean BMI was 24 kg/m2 and it did not increase in this 
population during two years of follow-up. Histological damage was more 
likely to progress in diabetic patients, but the diff erence did not reach sta-
tistical signifi cance (p=0.06).
Neither AR nor CMV infections were associated with ΔCADI. Th e ef-
fect of SAR or borderline AR detected at 3 months on the histology at 
one year was analyzed in Study II. Th ere was no diff erence in CADI score 
among those with or without SAR or borderline AR. Neither was a history 
of AR episodes associated with CADI at any time point.
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8.8. CADI and ΔCADI as predictors of long-term kidney 
allograft function
CADI in implant biopsies, CADI at 6 months, and the diff erence between 
these two values (ΔCADI 0–6) correlated positively with serum creatinine 
at hospital discharge, 6 months, 12 months and two years aft er transplanta-
tion (Study I). Overall, CADI and ΔCADI 0–6 correlated positively with 
kidney allograft  function at all time points, with the exception of CADI 
in implant biopsies and 12-month creatinine. Logistic regression analysis 
showed that the risk for having an abnormal serum creatinine concentra-
tion at two years from transplantation (i.e.> 115 μmol/L) was increased 
by 29% for each degree of increase in ΔCADI 0–6. Th e biopsies were sub-
divided into those with ΔCADI 0–6 > 1 and ≤1 and compared to kidney 
allograft  function during two years of follow-up. Th e results of this analysis 
are shown in Figure 13.
Figure 13. Mean serum creatinine (with 95% confi dence intervals) in patients with 
ΔCADI >1 and patients with ΔCADI ≤1 at hospital discharge, biopsy time, one year 
and two years.
In Study II, kidney allograft  function was estimated with the Cockcroft  & 
Gault formula (e-GFR). CADI in all biopsies correlated negatively with 
eGFR at 18 months. A similar observation was made for ΔCADI 0–6 mo 
and ΔCADI 0–12 mo. In contrast, ΔCADI 3–12 mo did not correlate sig-
nifi cantly with eGFR. Th e presence of CAN at 3 months did not have any 
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impact on eGFR at 18 months. However, IFTA (interstitial fi brosis plus 
tubular atrophy) at 3 months correlated negatively with eGFR (R -0.47; 
P=0.004). Both CAN and IFTA at 6 or 12 months were inversely related to 
lower e-GFR at 18 months. Lower creatinine concentrations at 24 months 
were observed in the all-study comparison, and the diff erence between 
Studies III and IV was statistically signifi cant (P=0.021) and also between 
Studies II and III (P=0.020). 
8.9. Impact of SAR and borderline AR on long-term 
allograft function 
Th e impact of AR and SAR on long-term allograft  function was not ana-
lyzed separately in Studies I and IV due to the small number of such cases 
(3%). In Study II, patients with SAR and borderline AR were pooled, and 
their eGFR was compared to that of patients without these histological fea-
tures. Kidney allograft  function was found to be similar in both groups. 
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9. Discussion
Th is Study included protocol biopsies obtained in a 14 year period of time. 
Th e results of this thesis can be divided into two eras: the periods before 
and aft er the year 2001. Over these years, the prevalence of CAN changed 
and the patients´ treatment as well. Th e quality of the donors has worsened 
but immunosupression and treatment of HT and metabolic disturbances 
were intensifi ed along the years in this study population. Th e individual ef-
fect of these aspects on the pathophysiology of CAN is discussed below.
9.1. Pathophysiology of CAN
Before 2001 more kidneys from male donors aft er traumatic (i.e. accidental) 
death were transplanted, directly infl uencing the mean donor age in this 
period. Aft er 2001 the trend was reverted: there was a signifi cant increase in 
donor age, and the donors were mainly women whose death oft en resulted 
from an underlying disease. A similar observation was made in another 
study on the Finnish transplant population in 2005 (Kyllönen, 2005) and 
in a study based on the United Network of Organ Share (UNOS) data. (Su, 
2004) Th is shows that the shortage of organs has prompted transplant physi-
cians to accept kidneys from donors who in the past were considered mar-
ginal. Th e increased probability of accepting kidneys with some degree of 
damage is, however, overwhelmed by the longer survival and quality of life 
of the transplanted patients. Th e present study showed that older donor age 
and non-traumatic cause of death increase the probability of donor kidney 
damage, such as glomerulosclerosis, interstitial fi brosis and vasculopahty. 
A proposed approach to the problem of marginal donors is be to evalua te 
implant biopsies from older donors before accepting their kidneys for 
transplantation. In a study conducted in 2006, a score grading of implant 
biopsies was proposed as a tool to decide whether the kidney was suitable 
for transplantation. Aft er 23 months of follow-up, histologically evaluated 
kidneys from donors older than 60 years had similar graft  survival as kid-
neys from younger donors. Th e stratifi cation of the kidneys from donors 
over 60 years of age, based of histological grading, resulted in a lowered 
prevalence of DGF, when compared to kidneys transplanted without this 
histological evaluation.(Remuzzi, 2006) In our Hospital a histopathologi-
cal evaluation of implant biopsies of marginal donors before proceeding to 
implantation has not been done. In this Study absolute normal histology 
was found in one third of implant biopsies. Th e most common fi nding in 
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those with a CADI score ≥1 was glomerulosclerosis, and this fi nding was 
shown to be of prognostic value. A 1% increase of glomerulosclerosis in 
implant biopsies increased the risk for histologic damage progression and 
it was also associated with worse KTX function. It can be hypothesized that 
a thorough pathological evaluation before acceptance might prevent the 
progression of CAN in two thirds of the KTX. 
In the studies included in this thesis, only data on CIT were collected, as 
information on the length of time between brain death and kidney harvest-
ing was not available. Considering that free-radical-mediated injury starts 
before brain death and continues during organ preservation, shortening 
the CIT may reduce this type of injury. Brain death is associated with an 
autonomic storm that leads to tissue hypoperfusion and thus accumulation 
of free radicals. In addition, a systemic infl ammatory response takes place, 
manifested by the upregulation of proinfl ammatory cytokines. Interstitial 
leukocytes and E-selectin adhesion molecules were detected in kidneys 
from cadaver donors when compared to living donors. TGF-β seemed to 
have a role in this process. (Nijboer, 2004) In a study from the year 2003, 
the oxidative stress in the kidneys from brain death donors was evaluated. 
A high concentration of malondialdehyde and low total antioxidant status 
were associated with poor short-term as well as long-term graft  survival.
(Kosieradzki, 2003) Th erapies in which the cadaver donor is treated with 
antioxidant agents before kidney harvesting seem promising, but they re-
quire further investigation in large clinical trials.
Th e negative change in the quality of donors witnessed over the years 
may explain the considerable increase in the incidence of DGF from 23 
to 37% before and aft er the year 2001, respectively. A report from UNOS 
stated that the prevalence of DGF was 22% in 1991 and 25% in 2003.
(Cecka, 2003) DGF is directly infl uenced by donor age, CIT and hypo-
volemia.(Nyhof, 2005) Biopsies from patients with DGF may reveal acute 
tubular necrosis, AR or CNI toxicity. Th e policy in our Hospital consists 
in a protocol biopsy evaluation in patients with DGF. Although DGF did 
not prove to be a risk factor for CAN progression in the present Study, an 
elevated level of serum creatinine at hospital discharge was. Th is may have 
been the consequence of either DGF or graft s starting to function slowly. 
In a retrospective study on 611 KTX patients, the presence of concomitant 
AR and DGF shortened graft  survival time independently of the duration 
of CIT. Prolonged CIT nevertheless seemed to predispose to AR, explain-
ing why a stronger immunosuppressive regimen was proposed in this 
situa tion. (Mikhalski, 2008) In the population investigated in this thesis, 
the stronger factor infl uencing the increased prevalence of DGF was the 
older age of the donors, given the low prevalence of severe AR, rare CNI 
toxicity, and unchanged CIT. 
Th e mean HLA mismatches remained nearly unchanged over the time, 
and CIT seldom exceeded 24 h in the present study. Lately, the kidney al-
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lograft  allocation based on HLA matching has been criticized in the USA 
because it delays the whole allocation process, consequently prolonging 
CIT. (Salahudeen, 2004) Also the impact of HLA mismatch on graft  sur-
vival in the modern era of more potent immunosuppressive agents has 
been questioned. (Su, 2004) However, a large European study concluded 
that HLA matching still infl uences graft  outcome positively. (Opelz, 2007) 
Th e kidney allocation policy in Finland is based on HLA matching and 
has led to excellent long-term results without signifi cantly aff ecting CIT.
(Salmela, 2004)
Th e nephrotoxicity of CNI is a side eff ect which comes along with its 
immunosuppressive eff ect. Th us, the options are to either avoid CNI or 
to use lower doses. Th e defi nition of a low dose is, however, diffi  cult to 
determine because of the great variation in the risk profi les of diff erent pa-
tients. Th ere is evidence that minimizing or avoiding the use of CNI is safe 
and effi  cient, when established at least three months aft er transplantation. 
(Haller, 2009) In the Elite-Symphony study, the standard CsA through 
level ranged from 100–200 μg/L three months aft er transplantation, and 
the low-CsA target was 50–100 μg/L. Th e low-dose CsA concentrations 
mentioned above are actually standard target concentrations for the Finn-
ish population, and might explain the low prevalence of CsA toxicity re-
ported in the present study. Th e great variability in the absorption profi les 
of patients led to the development of a more predictable formulation of 
CsA, i.e. the microemulsion. (International Neoral Renal Transplantation 
Study Group, 2002) Th e patients included in the present study were all on 
CsA-microemulsion therapy. Due to the fact that optimal CsA exposure is 
critical in preventing both nephrotoxicity and under-immunosuppression, 
it is of utmost importance to evaluate the tools available for accomplishing 
it. In this study CsA exposure was monitored with through concentrations, 
C0. In accordance to the recommendations presented in the literature in 
recent years (Citterio, 2005; Dominguez, 2005; Pallardo, 2007), C2 was also 
measured concomitantly with protocol biopsies. Th e fi rst limitation for the 
analysis was that the measurement of the CsA concentration within a time 
frame of 2 h ± 15 min succeeded in only 44% of the CsA users. Th e ben-
efi ts of C2 monitoring have been described in many randomized control-
led trials. Th e rate of successful C2 measurement in regular clinical prac-
tice, beyond rigorously controlled trials, has not been reported, however. 
Among the factors that may have aff ected the low percentage of successful 
C2 measurements in the present study are: the place where the samples 
were obtained (a busy laboratory of a general hospital), and insuffi  cient 
information given to the patients and to the staff  stressing the importance 
of the timing related to the procedure. 
Th e hallmark of CsA nephrotoxicity is striped interstitial fi brosis.(Cat-
taneo, Zenoni et al. 2005) Th e present study was unable to show an asso-
ciation between either C0 or C2 and IFTA in protocol biopsies. A possible 
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explanation for this may be that IFTA is the result of many factors in ad-
dition to CsA. Kidneys biopsies from patients on CsA had enhanced the 
expression of TGF-β, and it has been suggested that CsA nephrotoxicity 
occurs via a TGF-β dependent pathway, although the exact mechanisms 
underlying this relationship are not completely understood.(Jain, 2002) 
In accordance with the above results, the decrease in CsA dose directly 
lowered the serum concentration of TGF-β and improved kidney func-
tion.(Hueso, 1998) Th e present study is the fi rst one to report an associa-
tion between C2 and TFG-β1 expression in protocol biopsies. Th e TGF-β1 
staining of implant biopsies was not possible, but the expression of TGF-β1 
did not increase from 3 to 12 months. An increasing expression of TGF-β1 
was reported in sequential protocol biopsies in the literature.(Jain, 2002) 
Th is discrepancy may be explained by the low CsA targets in the popula-
tion of the present study, which is in accordance with the low incidence 
of CsA toxicity. Th e signifi cance of the expression of TGF-β1 in infl amma-
tory cells is not known, but could be the consequence of under-exposure 
to CsA, leading to immune activation. An interesting observation in this 
study was the negative correlation between C2 and TGF-β1 expression in 
infl ammatory cells. Recently, more attention has been paid to the sub-
capsular and perivascular infl ammatory infi ltrates detected in kidney bi-
opsies, previously not believed to be of prognostic value. Th e last report 
on the Banff  classifi cation recommends scoring of the total infl ammation 
and revision of this concept in future meetings.(Solez, 2008) In the light 
of the present study, the staining for TGF-β1 may bring valuable informa-
tion about the pathophysiology of CAN. C2 below 450 μgl/L at one year 
post-transplantation was associated with an increased total expression of 
TGF-β1, and particularly in the vessels. Th e increase in the expression of 
TGF-β1 in the vessels may be paralleled by the increase in chronic vascu-
lopathy revealed by light microscopy. It can be hypothesized that TGF-β1 
contributed to the development of allograft  vasculopathy. An association 
between TGF-β1 expression and kidney function in the 6-month biopsies 
may add prognostic value to this fi nding. According to the results of the 
present study, a C2 target < 600 μg/L at one year might be discouraged in 
this patient population.
A drawback of low-CNI regimens or discontinuation of CNI is the 
increased risk of AR. Th at is why these regimens are usually associated 
with the initiation of an m-Tor inhibitor.(Fellström, 2004) In the present 
study, replacing CNI by rapamycin was acknowledged in one case only. 
Th e cumulative incidence of AR in this study was dramatically reduced 
from 36 to 14% before and aft er the year 2001, despite the relatively low 
daily doses of CsA and through target concentrations. In the present study, 
AR was not a risk factor for progression of CADI. Th is may be due to the 
fact that the majority of the AR were mild, steroid-sensitive and occurred 
early, i.e. before the third month. In addition to this, the prevalence of SAR 
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was constantly low in this study. Before 2001, when the standard immu-
nosuppression regimen consisted of CsA, azathioprine and steroids, the 
incidence of AR was 36% and that of SAR 3%. Aft er 2001 tacrolimus was 
used more frequently and, as mentioned earlier, azathioprine was replaced 
by MMF in the treatment of new transplant patients. In this latter period, 
the incidence of AR fell to 14% and the prevalence of SAR remained un-
changed. Even patients in whom SAR was detected did not have a more 
adverse outcome than those free of SAR. It is worth mentioning that in 
half of the SAR cases the immunosuppression regimen was modifi ed aft er 
the protocol biopsy. At 3 months, 73% of the protocol biopsies displayed 
an almost normal histology, and SAR was found in only 7%. Th is subgroup 
of SAR was not treated, and the tubulitis had spontaneously resolved in 
a subsequent biopsy. On the contrary, protocol biopsies at 6 months re-
vealed more commonly chronic damage, and this correlated with worse 
kidney allograft  function at two years. In these biopsies the incidence of 
SAR was 4%. Th is subgroup of patients was treated by increased immuno-
suppression and stricter follow-up. Whenever CAN was present in 6- and 
12-months protocol biopsies, ACEi or ARB therapy was considered. Un-
fortunately, a follow-up protocol biopsy was not available from all these 
patients for evaluating the effi  cacy of these measures. 
In the present study, the CADI score in 6-month biopsies fell from 3.27 
to 1.55. Although the causes of this remarkable improvement may be mul-
tifactorial, a crucial change in drug therapy took place in 2003, when aza-
thioprine was substituted with MMF. Th e more active use of ACEi/ARB 
and statins may also have played a role in this improvement. An increase 
in mesangial matrix correlated with total cholesterol and LDL. High HDL 
correlated with a decrease in the progression of chronic vasculopathy. Stat-
ins were more frequently prescribed aft er 2001, and this might in part ex-
plain the better dyslipemia profi le described in 8.7. Similarly, the number 
of patients under drug treatment for hypertension increased over the years, 
and ACEi/ARB were the most commonly used drugs. Th is study showed 
that tubular atrophy was associated with hypertension, and that the pro-
gression of CAN was directly related to high diastolic blood pressure. A 
randomized controlled trial involving 162 KTX patients compared the ef-
fect of losartan, captopril or amlodipin on plasma concentration of TGB-β1 
and histopathological changes in serial biopsies. Th e authors found that 
biopsies from patients treated with losartan showed less progression of the 
histological changes and reduced plasma TGB-β1 (el-Agroudy, 2003). Ran-
domized controlled trials demonstrating prolonged graft  and or patient 
survival attributable to treatment with ACEi/ARB or statins are still lack-
ing (Cruzado, 2008). However, the present results support the use of these 
drugs to slow the progression of CAN.
Th e most common etiologies found in this study – diabetic nephro-
pathy, chronic glomerulonephritis, and polycystic kidney disease – are in 
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agreement with the epidemiological data from the Finnish Kidney Trans-
plant Registry (www.musili.fi /smtr) Although the etiology of primary kid-
ney disease does not seem to aff ect CAN, patient survival might be aff ected 
if the follow-up period is long enough. In the present Study follow-up was 
limited to 2 years, and de novo or recurrent disease was seldom seen. In 
a large retrospective study including over 105,000 patients from UNOS 
and the United States Renal Data System (USRD), one fi ft h of the recipi-
ents had a history of cardiovascular disease pervious to KTX. Th e most 
common cardiovascular diseases were unstable angina pectoris, coronary 
artery disease, and congestive heart failure. Aft er 8 years’ follow-up, both 
graft  and patient survival were diminished if cardiovascular disease had 
been present prior to transplantation. Particularly diabetic recipients had 
a signifi cantly higher prevalence of cardiovascular disease than non-dia-
betics (46 vs. 15%, respectively). Th e diagnosis of congestive heart failure 
or arrhythmia in this population was associated with worst graft  survival. 
(Petersen, 2007) An abnormal glucose metabolism has been associated 
with poor patient survival, mainly due to death secondary to cardiovascu-
lar events. (Petersen, 2007 ; Hjelmesaeth, 2006) Graft  survival was reported 
to be shortened in patients with PTDM, (Kasiske, 2003) but a relationship 
between abnormal glucose metabolism and CAN is missing. In the present 
study, a trend towards progression of histological damage in diabetics was 
observed. Th e lack of statistical signifi cance (P=0.06) may be related to 
the fact that diabetic nephropathy is a slowly progressing disease, and the 
follow-up in this study was limited to two years. Th e lack of systematic 
protocol biopsies beyond the fi rst year is another limitation to evaluating 
the impact of PTDM or IGT on the progression of CAN.
9.2. Tools for clinical surveillance of kidney allograft 
status
It has been generally accepted that the “well being” of kidney allograft s is 
refl ected by normal kidney function. Th is view was proven incorrect over 
15 years ago when biopsies obtained from normally functioning kidney 
allograft s displayed chronic damage. (Isoniemi, 1992; Freese, 2001, Leg-
endre, 1998) In contrast, biopsies from suboptimally functioning kidney 
allograft s can appear normal. Th e latter situation evidences the limitations 
of making an inference from a biopsy sample to represent the whole kidney 
allograft , the so-called sample bias. Sample bias may explain the negative 
ΔCADI scores obtained in some cases in this study. Another possible ex-
planation is that among the CADI score components, infl ammation, un-
like fi brosis or tubular atrophy, may resolve over the time.
Protocol biopsy has been postulated as an appropriate surrogate of 
late graft  function in clinical trials.(Mengel, 2007) It is also the standard 
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practice of care in many transplantation centers. Protocol biopsies have 
become more popular lately, despite the lack of consensus regarding this 
policy. Transplantation centers with a great deal of experience on this pro-
cedure have not yet proposed any suggestion about the timing of protocol 
biopsies. Th ere is agreement concerning the necessity of protocol biopsies 
to monitor kidney allograft s in the case of DGF, high-risk cross-match-
positive patients, and ABO incompatibility.(Nankivell, 2006) Two diff er-
ent timings for protocol biopsies were compared in the present Study. In 
this population, a protocol biopsy obtained at 3 months displayed substan-
tial histological changes in only 27% of the cases and did not predict late 
histological damage. Biopsy fi ndings correlated with estimated GFR at 18 
months, but did not add crucial information to that obtained from implant 
biopsies. Protocol biopsies obtained at 6 and 12 months revealed a wide 
variety of chronic changes that were of prognostic value for late graft  func-
tion. Furthermore, the recognition of histological changes, both acute and 
chronic, helped clinicians to make modifi cations in the drug treatment of 
the recipients. 
Although the protocol biopsies provided information that cannot be 
obtained in any other way, the most trusted everyday tool for monitoring 
kidney allograft  function is the measurement of serum creatinine concen-
tration. Serum creatinine has a poor sensitivity in detecting small changes 
in GFR, (Hoek, 2003) a highly critical situation especially in the moni-
toring of early kidney transplants. Th e search for another clinically useful 
biochemical marker of GFR led to the thorough evaluation of CyC as a 
suitable candidate. A notable drawback of CyC is the infl uence of gluco-
corticosteroids on its concentration, independently of variations in GFR.
(Risch, 2001) Th is is a defi nite disadvantage when high steroid doses are 
needed to treat AR, making CyC useless for monitoring a graft  recovering 
from the insult. Th e present study assessed whether CyC was more sensitive 
than creatinine for predicting CAN. Th e results pointed to a better positive 
and a negative predictive value of creatinine compared to CyC. It was not 
possible to determine whether the small dose of methylprednisolone used 
by 94% of the patients could have exerted an infl uence on these results. 
Numerous studies favor CyC as a better estimator of GFR, particularly in 
children and in patients whose GFR is slightly reduced. Several formulas 
have been proposed for estimating GFR based on CyC.(Filler, 2008; White, 
2007) Th e discrepancy in the literature may be due to the diff erences in the 
populations studied and the variability in CKD stage, and the gold stand-
ard method employed. (Zahran, 2007) Based on the results of the present 
study, measurement of CyC aff orded no benefi t in the case of adult kidney 
transplants.
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10. Conclusions
Th e progression of CAN in the present study seems to be aff ected by two 
major factors: the quality of the donor kidney and suboptimal control of 
the recipient’s blood pressure. Th e age of donors has been on the rise in 
recent years due to the shortage of organs. Cadaver donors are more oft en 
females and with an underlying disease. Th is may explain the increasing 
prevalence of DGF found in this study. Careful hemodynamic control of 
the cadaver donor and eff orts to shorten CIT are mandatory. Evaluation 
of biopsies from marginal kidneys prior to implantation is a strategy that 
ought to be considered, as it might infl uence CAN progression. 
Diastolic blood pressure was associated with progression of CAN. Not 
only hypertension, but also dyslipidemia was associated with mesangial 
matrix expansion. Th ese changes progressed already in the fi rst 6 months 
aft er transplantation. Th e results may encourage the use statins and ACEi/
ARB more widely to slow down the progression of CAN.
Implant biopsies proved to be of prognostic value, and they are essential 
for comparison with subsequent biopsies. Compared to implant biopsies, 
protocol biopsies at 3 months did not aff ord substantially superior prog-
nostic value, and were not followed by modifi cations in the treatment. Pro-
tocol biopsies at 6 and 12 months were suitable surrogates of late kidney 
allograft  function, and impacted the clinical management of the patients. 
Th e eff ect of this policy on CAN progression could not be evaluated, be-
cause this is an observational study. Nevertheless, the modifi cations to the 
treatment based on protocol biopsies may have contributed to the decrease 
in CADI score during the course of the study.
Th e prevalence of SAR was low in the present study, and AR was sig-
nifi cantly reduced, despite the modest immunosuppressive treatment. 
Th e relevance of the expression of TGF-β1 in infl ammatory cells remains 
to be confi rmed, but it may be related to low immunosuppression. Th us, 
a CsA level below 600 μg/L at one year might be discouraged. Biopsies 
from patients with even lower C2 targets showed increased expression of 
TGF-β1 in the vessels, an observation that was linked to the progression of 
chronic vasculopathy in the graft . Th e expression of TGF-β1 in infl amma-
tory cells of protocol biopsies was related to weaker graft  function during 
follow-up.
Th e factors involved in the progression of CAN and the proposed strat-
egies to manage it are summarized in Figure 14.
In routine clinical follow-up, creatinine measurement continues to be 
the most feasible way to monitor the function of kidney allograft s, even 
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though its sensitivity to detect CAN is low. Protocol biopsies at 6 mo thus 
constitute a suitable surrogate to be used in clinical trials, and an advisable 
policy for the monitoring of kidney allograft s.
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11. Finnish summary (Yhteenveto)
Tausta. Munuaissiirto on paras tapa hoitaa kroonista munuaisten vajaa-
toimintaa. Vaikka tulokset ovat parantuneet viime vuosina, huomattava 
määrä munuaissiirteistä menetetään siirtopotilaan ennenaikaiseen kuole-
maan ja pitkäaikaiseen siirrännäisen nefropatiaan (CAN). 
Tavoite. Analysoida CAN:in riskitekijöitä ja eri diagnostisten menetelmien 
arvoa.
Aineisto ja metodit. Yhteensä 153 luovuttajan munuaisbiopsiaa ja 364 siir-
teen protokollabiopsiaa otettiin kesäkuun 1996 ja huhtikuun 2008 välillä. 
Biopsiat luokiteltiin Banf ’97:n ja kroonisen allograft i-vaurio indeksin 
(CADI) mukaan. TGF-β1 ilmentyminen analysoitiin immunohistokemial-
lisesti 49:stä biopsiasta. Munuaisten toiminta arvioitiin kreatiniinin mää-
rityksellä ja lisäksi tietyillä suodatusnopeuden (GFR) ennustajilla. Luovut-
tajista ja saajista kerättiin kliinisiä tietoja 2 vuoden seurannassa.
Tulokset. Kolmen kuukauden biopsiat olivat lähes normaaleja 73 %:ssa ta-
pauksista. CADI laski merkitsevästi kuuden kuukauden biopsioissa vuo-
den 2001 jälkeen. Diastolinen hypertensio korreloi CADI:n etenemiseen 
(ΔCADI). Seerumin kreatiniinin pitoisuus potilaan kotiutuessaan sairaa-
lasta ja glomeruloskleroosi osoittautuivat ΔCADI:in riskitekijöiksi. Suuri 
kokonais- ja LDL-kolesterolin pitoisuus, pieni HDL pitoisuus ja hyper-
tensio korreloivat histologisiin muutoksiin. Luovuttajien keski-ikä nousi 
41:sta 52 vuoteen. Ikääntyneet luovuttajat olivat useammin kuolleet jo-
honkin sairauteen. Viivästynyt siirrännäisen toiminta lisääntyi viime vuo-
sina, samalla kun akuutit hyljinnät harvinaistuivat. Sub-kliinisen akuutin 
hyljinnän insidenssi oli vain 4 % eikä se vaikuttanut pitkäaikaiseen siir-
teen toimintaan eikä CADI:iin. Potilaiden lääkehoito muuttui siten, että 
vuoden 2001 jälkeen mykofenolatti mofetiilia, takrolimuusia, statiineja ja 
renini-angiotensiini-estäjiä käytettiin aiempaa useammin. Vakavia seura-
uksia protokolla biopsian otosta ei todettu. 
Potilaat, joilla ΔCADI oli korkea, oli huonompi GFR kahden vuoden 
jälkeen. Seerumin kreatiniini ennusti parhaiten CADI>2 tapauksia, vaikka 
sen herkkyys ja spesifi syys oli vaatimaton. Muut GFR:n ennustekaavat 
tai plasman kystatiini C: pitoisuus eivät olleet kreatiniinia parempia. Vä-
likudoksen tulehduksellisten solujen TGF-β1 ekspressio korreloi pieneen 
syklosporiini A:n 2 tunnin pitoisuuteen ja ennusti huonontuvaa siirteen 
toimintaa. Syklosporiini A:n toksisiteetti oli harvinaista.
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Päätelmät. Kaksi tärkeää tekijää vaikutti CAN etenemiseen: luovuttajien 
ominaisuudet ja saajien hypertensio. Luovuttajien ikään vaikutti elinten 
huono saatavuus. Luovuttajat olivat usein iäkkäitä perussairauteen kuol-
leita naisia, mikä selittänee viivästyneen siirrännäisen toiminnan. Luo-
vuttajien biopsiat ovat hyödyllisiä ennusteen arvioinnissa, ja ne ovat myös 
välttämättömiä vertailussa muihin biopsioihiin. Histologisen vaurion ete-
neminen assosioitui hypertensioon ja dyslipidemiaan. Tulehduksellisten 
solujen TGF-β1 ekspressio saattaa olla riittämättömän immunosuppression 
seuraus. Kuuden kuukauden ja vuoden protokollabiopsiat olivat kelvollisia 
myöhäisen siirteen toiminnan ennustajia ja ne vaikuttivat myös potilai-
den hoitoon. Seerumin kreatiniinitason pitoisuuden mittaus on paras tapa 
seurata munuaissiirteen toimintaa rutiininomaisesti, mutta protokolla-
biopsiat ovat tärkeitä paitsi kliinisissä tutkimuksissa niin myös suositeltava 
tapa seurata munuaissiirtoja. 
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